A weakened interface in the P182L variant of HSP27 associated with severe Charcot-Marie-Tooth neuropathy causes aberrant binding to interacting proteins

T Reid Alderson¹,²,³,‡, Elias Adriaenssens³,⁴, Bob Asselbergh⁴,⁵, Iva Pritišanac⁶, Jonas Van Lent³, Heidi Y Gastall³, Marielle A Wälti⁵, John M Louis⁵, Vincent Timmerman³,⁴,†, Andrew J Baldwin²,*** & Justin LP Benesch¹,***

Abstract

HSP27 is a human molecular chaperone that forms large, dynamic oligomers and functions in many aspects of cellular homeostasis. Mutations in HSP27 cause Charcot-Marie-Tooth (CMT) disease, the most common inherited disorder of the peripheral nervous system. A particularly severe form of CMT disease is triggered by the P182L mutation in the highly conserved IxI/V motif of the disordered C-terminal region, which interacts weakly with the structured core domain of HSP27. Here, we observed that the P182L mutation disrupts the chaperone activity and significantly increases the size of HSP27 oligomers formed in vitro, including in motor neurons differentiated from CMT patient-derived stem cells. Using NMR spectroscopy, we determined that the P182L mutation decreases the affinity of the HSP27 IxI/V motif for its own core domain, leaving this binding site more accessible for other IxI/V-containing proteins. We identified multiple IxI/V-bearing proteins that bind with higher affinity to the P182L variant due to the increased availability of the IxI/V-binding site. Our results provide a mechanistic basis for the impact of the P182L mutation on HSP27 and suggest that the IxI/V motif plays an important, regulatory role in modulating protein–protein interactions.

Keywords charcot-marie-tooth disease; intrinsically disordered regions; molecular chaperones; NMR spectroscopy; short linear motif

Subject Categories Neuroscience; Translation & Protein Quality

DOI 10.15252/embr.2019103811 | Received 5 November 2019 | Revised 10 January 2021 | Accepted 14 January 2021 | Published online 1 March 2021

Introduction

HSP27 (also known as HSBP1) is a systemically expressed small heat-shock protein (sHSP) that performs diverse functions under basal and stressful cellular conditions (Kampinga et al, 2015; Janowska et al, 2019; Mogk et al, 2019). With significant roles in the maintenance of protein homeostasis, regulation of the redox environment, prevention of apoptosis, and stabilization of the cytoskeletal network, the biological activity of HSP27 is critical to overall cellular health (Bruey et al, 2000; Arrigo, 2001; Straume et al, 2012), neurodegenerative diseases (Outeiro et al, 2006), and neuropathies (Evrgrafov et al, 2004). More than 30 heritable HSP27 mutations are implicated in Charcot-Marie-Tooth (CMT) disease (Nefedova et al, 2015; Adriaenssens et al, 2017; Echaniz-Laguna et al, 2017; Muranova et al, 2020; Vendredy et al, 2020), a group of neuropathies that affects ca. 1 in 2,500 individuals and is the most common inherited disorder involving the peripheral nervous system (Barisic et al, 2008; Timmerman et al, 2014). CMT disease is characterized by progressive demyelination (type 1 CMT), axonal loss (type 2 CMT), or their combination (Rossor et al, 2013; Pipis et al, 2019). When the affected axons exclusively include motor neurons, the disease is referred to as distal hereditary motor neuropathy (dHMN) (Rossor et al, 2013; Beijer & Baets, 2020). Transgenic HSP27 mouse models develop CMT disease-like symptoms...
(D’Ydewalle et al., 2011), thereby implicating HSP27 as a direct driver of CMT disease onset.

HSP27 contains three domains: a conserved α-crystallin domain (ACD) that is flanked by an N-terminal domain (NTD) and a C-terminal region (CTR), which is disordered and contains a highly conserved IxI/V motif. Similar to the roles of other intrinsically disordered protein regions (Wright & Dyson, 2014), the CTRs of sHSPs play key roles in promoting solubility and contributing to the regulation of interactions with other proteins (Carver et al., 2017; Holt et al., 2019), including liquid–liquid phase separation (Morelli et al., 2017). Biophysical studies on HSP27 and related sHSPs have shown that intermolecular contacts between all three domains (Hochberg & Benesch, 2014; Haslbeck & Vierling, 2015; Clouser et al., 2019; Kaiser et al., 2019) facilitate the assembly of large, dynamic oligomers with an average mass near 500 kDa (Jehle et al., 2010; Baldwin et al., 2011, 2012; McDonald et al., 2012; Hochberg et al., 2014). In mammalian sHSPs, the central residue in the IxI/V motif is generally proline, and this short linear motif (SLIM) is involved in binding to the structured ACD. High-resolution structures have been obtained for the ACD (Rajagopal et al., 2015) bound to a peptide containing the IxI/V motif (Hochberg et al., 2014). In addition, the IxI/V motif can facilitate interactions between HSP27 and other proteins that contain this motif, including the HSP70 co-chaperone Bcl-2-associated anthanogene-3 (BAG3) (Rosati et al., 2011), which contains two IxI/V motifs and forms an HSP27-BAG3-HSP70 ternary complex that enables substrate transfer between the two chaperones (Rauch et al., 2017).

While the majority of CMT-associated mutations in HSPB1 reside in the structured ACD (Adriaenssens et al., 2017; Weeks et al., 2018), mutations within the disordered NTD and CTR also cause CMT disease (Chalova et al., 2014; Muranova et al., 2015). One of the most clinically severe variants is caused by the P182L mutation, which falls in the intrinsically disordered CTR and changes the highly conserved Pro residue within the IxI/V motif (Ile-Pro-Val187 in HSP27) to a Leu. Symptoms caused by the P182L mutation typically manifest within the first 5 years of life, whereas mutations in the ACD generally result in adult-onset symptoms (Dierick et al., 2014). Pro182 is the only residue within the IxI/V motif that is implicated in CMT disease; however, the molecular basis of the impacts of the P182L mutation remains unknown.

Here, we sought to understand the biophysical significance of the P182L mutation in HSP27. We observed that the P182L mutation significantly increases the average molecular mass of soluble HSP27 oligomers and disrupts its ability to prevent substrate aggregation. Expansion microscopy, which enables imaging at the single molecule level, revealed that the P182L variant forms larger oligomers in vitro. These large P182L oligomers were also detected in induced pluripotent stem cells (iPSCs) from a CMT patient containing the P182L mutation. We investigated the binding of the IxI/V motif to the ACD with NMR spectroscopy, revealing that the affinity of the P182L variant is decreased by an order of magnitude. This suggests that the weakened affinity for the ACD causes the IxI/V motif binding site to become more exposed for other IxI/V-containing proteins. We verified this hypothesis by demonstrating that a number of IxI/V-containing proteins, including BAG3, an HSP70 co-chaperone with two IPV motifs, bind with enhanced affinity for the P182L variant of HSP27. We validated these results with targeted mutations that either disrupt the IxI/V motif of the interactor or the ability of HSP27 to bind to IxI/V motifs. Given the highly conserved nature of the IxI/V across sHSPs, our findings suggest that this motif plays a regulatory role in mediating interactions among this important family of molecular chaperones.

**Results**

To shed light on the structural impact of the P182L mutation (Fig 1A and B), we investigated the biophysical and functional properties of the wild-type (WT) and P182L variants of full-length HSP27. Our experiments also used the isolated ACD (Fig 1C) to characterize the binding of the IxI/V motif in its WT and P182L forms. The ACD folds into a β-strand-rich dimer (Fig 1D) and the IxI/V motif binds to the ACD in the groove located between the β4 and β8 strands (Fig 1D) through hydrophobic interactions and hydrogen bonds to the backbone atoms of V111, T113, and L157 (Fig 1E). In WT HSP27, the IxI/V motif is manifested as 181IP1V183, and the Ile and Val residues penetrate the hydrophobic β4/β8 groove in the ACD (Fig 1E).

**The P182L variant has impaired chaperone activity**

To determine the effect of the P182L mutation on the chaperone activity of HSP27, we purified recombinant human HSP27 and the CMT-implicated P182L variant and tested their ability to prevent the aggregation of two model substrate proteins, malate dehydrogenase (MDH) and insulin. The WT form of HSP27 proved highly effective at inhibiting the aggregation of both substrates (Fig 1F and G, red traces), as observed previously and indicative of its potent anti-aggregation activity (Alderson et al., 2019). However, the P182L variant was unable to prevent the aggregation of either substrate (Fig 1F and G, blue traces), revealing a drastic loss of function in vitro (Appendix Fig S1A). Indeed, based on the elevated light scattering in the presence of the chaperone, the P182L form of HSP27 appeared to co-aggregate with MDH and insulin. Control experiments indicated that the P182L variant does not aggregate appreciably when incubated alone at high concentrations and 40°C (Appendix Fig S1B) and is correctly folded (Appendix Fig S1C), suggesting that P182L is stable in solution and the loss of P182L chaperone activity is not due to misfolding or self-aggregation. This is consistent with the CMT-causing P182S mutant exhibiting similar thermal stability to the WT protein, with respective melting temperatures of 64 and 70°C (Chalova et al., 2014). The absence of self-aggregation indicates that P182L promotes substrate aggregation under these conditions, as has been observed for other sHSP systems (Ungelenk et al., 2016), including the cardiomyopathy-causing R120G variant of αB-crystallin (Bova et al., 1999). The P182L mutation therefore prevents HSP27 from attenuating the aggregation of these client proteins.

**P182L forms large oligomers both in vitro and in vivo**

To understand the reduced chaperone activity of P182L, we used size exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) to characterize its oligomeric properties in solution. For WT HSP27 and its isolated ACD, the SEC-MALS data
revealed average molecular masses of approximately 500 and 20 kDa (Fig 2A), respectively. By contrast, the P182L variant formed large oligomers with an average molecular mass near 14 MDa (Fig 2A), almost a 30-fold increase over the WT protein. With a monomeric mass of 22.7 kDa, the P182L variant forms an oligomeric assembly comprising an average of ca. 620 subunits, whereas the WT protein forms oligomers centered on ca. 24 subunits. As deduced by SEC-MALS, the ensemble-averaged hydration radius of P182L at 38 nm is four-fold larger than the 9-nm oligomers formed by WT HSP27, consistent with a ca. 30-fold increase in mass.

To confirm these results by an independent method, we extracted whole cell protein lysates from HeLa cells stably overexpressing HSP27 WT or the P182L mutant and separated these protein lysates over a sucrose gradient. The respective fractions were loaded on Western blot and demonstrated a clear shift toward larger protein complexes for the P182L mutant (Fig 2B). Negative-stain electron microscopy (EM) also revealed the formation of larger P182L oligomers (Appendix Fig S2). Together, the SEC-MALS, sucrose gradient, and negative-stain EM data establish that the disease-causing P182L mutation shifts the oligomeric distribution of HSP27 toward significantly larger species.

To visualize these soluble oligomeric states of HSP27 in cells, we performed expansion microscopy, which allows imaging of HSP27 at the nanoscale and analysis of the distribution of soluble HSP27 in the cytoplasm. Expansion microscopy increases the effective resolution by more than four-fold compared to conventional microscopy (Chen et al., 2015). As a result, soluble HSP27 assemblies that were indistinguishable by standard confocal microscopy could be visualized individually in HeLa cells (Fig 2C). Comparing the number of detectable spots per cytoplasmic volume shows that expression of the P182L mutant leads to a two-fold reduction in the density of HSP27 assemblies (Fig 2D). Furthermore, the fluorescence intensity of each spot is determined by the number of HSP27 subunits and therefore reflects indirectly the size of the oligomeric assemblies. Our measurements indicated that the P182L mutation increases the proportion of spots with higher intensities (Fig 2E).

Overexpression of the P182L mutant has been reported to cause increased formation of large insoluble HSP27-containing cytoplasmic aggregates (Ackerley et al., 2006; Almeida-Souza et al., 2010; Haidar et al., 2019). Indeed, upon transient transfection of V5-epitope-tagged P182L HSP27 in HeLa cells, we found that more than 25% of cells contained large, high-intensity aggregates visible by conventional microscopy, whereas comparable transient expression of WT HSP27 caused aggregation in fewer than 2% of cells (Appendix Fig S3A and B). This was also confirmed by Western blotting, which showed a greater insoluble fraction for P182L compared to WT HSP27, while the sum of both the soluble and insoluble fractions indicated equal expression levels (Appendix Fig S3A and B). This was also confirmed by Western blotting, which showed a greater insoluble fraction for P182L compared to WT HSP27, while the sum of both the soluble and insoluble fractions indicated equal expression levels (Appendix Fig S3A and B).


generated assembly comprising an average of 620 subunits, whereas the WT protein forms oligomers centered on ca. 24 subunits. As deduced by SEC-MALS, the ensemble-averaged hydration radius of P182L at 38 nm is four-fold larger than the 9-nm oligomers formed by WT HSP27, consistent with a ca. 30-fold increase in mass.

To confirm these results by an independent method, we extracted whole cell protein lysates from HeLa cells stably overexpressing HSP27 WT or the P182L mutant and separated these protein lysates over a sucrose gradient. The respective fractions were loaded on Western blot and demonstrated a clear shift toward larger protein complexes for the P182L mutant (Fig 2B). Negative-stain electron microscopy (EM) also revealed the formation of larger P182L oligomers (Appendix Fig S2). Together, the SEC-MALS, sucrose gradient, and negative-stain EM data establish that the disease-causing P182L mutation shifts the oligomeric distribution of HSP27 toward significantly larger species.

To visualize these soluble oligomeric states of HSP27 in cells, we performed expansion microscopy, which allows imaging of HSP27 at the nanoscale and analysis of the distribution of soluble HSP27 in the cytoplasm. Expansion microscopy increases the effective resolution by more than four-fold compared to conventional microscopy (Chen et al., 2015). As a result, soluble HSP27 assemblies that were indistinguishable by standard confocal microscopy could be visualized individually in HeLa cells (Fig 2C). Comparing the number of detectable spots per cytoplasmic volume shows that expression of the P182L mutant leads to a two-fold reduction in the density of HSP27 assemblies (Fig 2D). Furthermore, the fluorescence intensity of each spot is determined by the number of HSP27 subunits and therefore reflects indirectly the size of the oligomeric assemblies. Our measurements indicated that the P182L mutation increases the proportion of spots with higher intensities (Fig 2E).

Overexpression of the P182L mutant has been reported to cause increased formation of large insoluble HSP27-containing cytoplasmic aggregates (Ackerley et al., 2006; Almeida-Souza et al., 2010; Haidar et al., 2019). Indeed, upon transient transfection of V5-epitope-tagged P182L HSP27 in HeLa cells, we found that more than 25% of cells contained large, high-intensity aggregates visible by conventional microscopy, whereas comparable transient expression of WT HSP27 caused aggregation in fewer than 2% of cells (Appendix Fig S3A and B). This was also confirmed by Western blotting, which showed a greater insoluble fraction for P182L compared to WT HSP27, while the sum of both the soluble and insoluble fractions indicated equal expression levels (Appendix Fig S3C and D). To avoid that our expansion microscopy data would be confounded by the presence of large cytoplasmic aggregates, we only included cells without large aggregates and confirmed that average fluorescence intensities in expansion microscopy images were similar for both genotypes (Appendix Fig S3E-H). Furthermore, P182L and WT HSP27 have the same integrated spot intensities, defined as the product of the individual spot intensity and the
Figure 2. The P182L variant of HSP27 forms larger oligomers both in vitro and in vivo.

A SEC-MALS data from WT HSP27 and the P182L variant, with cHSP27 included for comparison. All samples were injected at 40 µM concentration (monomer). The respective average molecular masses are 14 MDa, 470 kDa, and 18 kDa for P182L, WT HSP27, and cHSP27. The normalized UV signals are plotted on the left y-axis as solid lines, and the molecular masses are plotted on the right y-axis as circles.

B Fractionation of HeLa cells overexpressing either HSP27 or the P182L mutant by a 10–80% sucrose gradient. Western blot against anti-V5 is shown.

C Expression of V5-epitope-tagged HSP27 (WT or P182L mutant) in HSP27 knockout HeLa cells and immunostaining of HSP27. The scale bars correspond to the non-expanded dimensions, derived by dividing by the sample expansion factor of 4.3.

D The P182L mutation decreases the density of HSP27 spots upon detection of local fluorescence intensity maxima and quantification of the number of detected spots in expanded samples (n = 30). The error bar is the standard deviation for the different cytoplasmic regions. The asterisks correspond to a P < 0.0001 as obtained from a t-test.

E Distribution of the intensity of individual spots (n = 3,342) after Gaussian fitting of fluorescence intensity in the neighborhood of detected spots. The asterisks correspond to a P < 0.0001 as obtained from a Mann–Whitney U test. Data were plotted with a square-root transformation of the y-axis to improve the visualization of the complete distribution of intensities.

F Immunostaining of HSP27 (white) in motor neurons differentiated from CMT patient-derived iPSCs that harbor the heterozygous P182L mutation reveals large, cytoplasmic aggregates (center and right panels). The control motor neurons that contain WT HSP27 do not show evidence of any aggregates. The nucleus is stained with Hoechst (blue). Scale bar, 10 µm.

Source data are available online for this figure.
spot density (Appendix Fig S5G), which additionally confirm that the P182L and WT forms are expressed at similar levels. Combined, these results show that assemblies of the P182L mutant are larger and more sparsely distributed in the cytoplasm, consistent with a higher oligomeric state in vitro than the WT.

P182L is a heterozygous mutation, so CMT patients will carry one copy of the mutant allele and one of the WT. We therefore wondered if the larger P182L oligomers might be composed of mixtures of WT and P182L subunits due to hetero-oligomerization. To this end, we first tested whether the P182L variant can hetero-oligomerize with WT HSP27 in vitro. Gel filtration chromatography showed that WT HSP27 assimilates into the larger P182L oligomers (Appendix Fig S4A). To verify whether hetero-oligomerization also occurs in cells, we extracted protein lysates from HeLa cells that overexpress the V5-epitope-tagged P182L variant on top of the endogenous WT protein. A Western blot analysis showed that the P182L variant and WT protein indeed hetero-oligomerize and that the P182L variant can hetero-dimerize with WT HSP27 by forming an intermonomer disulfide bond at C137 (Appendix Fig S4B), the lone cysteine residue. Hetero-oligomerization was additionally confirmed by the observations that P182L increased the insoluble fraction of endogenous WT HSP27 (Appendix Fig S3D), and that WT HSP27 co-immunoprecipitated with P182L HSP27 (Appendix Fig S4C). Together, these data demonstrate that the P182L variant hetero-oligomerizes with WT HSP27 in vitro and in HeLa cells.

Finally, we sought to establish in a CMT patient-derived cell line whether P182L also exists in a larger oligomeric form than the WT protein. To this end, we used iPSCs from a CMT patient harboring the heterozygous P182L mutation that we differentiated to spinal motor neurons. When immunostained for HSP27 and imaged with confocal microscopy, the P182L motor neurons contained many bright aggregate-like clusters (Fig 2F), which were absent in the control iPSC line (Fig 2F) that expresses the WT form of HSP27. Taken together, these biophysical data and functional assays demonstrate that the P182L mutation increases the size of oligomers both in vitro and in vivo toward very large states that have aberrant activity in preventing protein aggregation.

The P182L mutation significantly lowers binding affinity for the IxI/V motif

To understand the molecular basis of the oligomeric dysregulation caused by the P182L mutation, we sought to characterize the binding interaction between the ACD and the IxI/V motifs of the WT form (181IPV183) and the P182L variant (181ILV183). Previous solution-state NMR studies of WT HSP27 observed resonances only from the disordered CTR (Carver et al, 1995; Alderson et al, 2017). We therefore turned to the isolated ACD, which forms a stable dimer (2 x 10 kDa) that has been characterized by solution-state NMR (Rajagopal et al, 2015; Clouser & Klevit, 2017; Alderson et al, 2019, 2020) and is known to bind to a peptide encompassing the IxI/V motif of the CTR (Delbecq et al, 2012; Hilton et al, 2013a; Hochberg et al, 2014; Hochberg & Benesch, 2014; Rauch et al, 2017; Freilich et al, 2018; Liu et al, 2018).

Using NMR spectroscopy, we determined the $K_d$ of the ACD binding to a peptide comprising the WT IPV motif (Fig 3A–C). Since the ACD was uniformly $^{15}$N labeled, each amide bond in the protein contributed a signal in the 2D $^1$H–$^{15}$N heteronuclear single quantum coherence (HSQC) spectrum (Fig 3A and B). During the peptide titration, increasing the amount of added peptide led to the disappearance of resonances from ACD residues in the $\beta_4/\beta_8$ groove (“slow” exchange) (Fig 3A) and progressive changes in the chemical shifts of other residues (“fast” exchange) (Fig 3B), i.e., chemical shift perturbations (CSPs). To a first approximation, analogous to a procedure described previously (Delbecq et al, 2012), we assumed that the group of continuously varying residues were in fast exchange and fit these resonances to equation 2 (see Materials and Methods) yielding a global $K_d$ of ca. 125 µM at 25°C (Fig 3C). Next, using the same approach, we measured the binding affinity of the peptide bearing the P182L mutation implicated in the onset of CMT (Fig 3A–C), revealing that the mutation lowers the binding affinity for the ACD by an order of magnitude from ca. 125 µM to 1 mM (Fig 3C), corresponding to a $\Delta G$ of ca. 5 kJ/mol at 25°C. Importantly, the resonances in the ACD reporting on the binding were the same for both the WT and P182L peptides, indicating the binding site is the same in both cases (Fig 3D and E).

In addition to monitoring structural changes to the protein upon binding, we also collected 1D NMR spectra of the isolated WT and P182L peptides. For both peptides, the resonances cluster in the disordered region of the $^1$H spectrum (8–8.5 ppm) (Appendix Fig S4E), indicating the absence of appreciable secondary structure in either peptide. This rules out that the difference in binding affinity between the P182L and WT peptides comes from a variation in their secondary structure. Our results thus demonstrate that the P182L peptide binds in the same site as the WT peptide but with significantly lower affinity, and elicits common structural changes to the ACD upon binding.

The IxI/V motif interconverts between multiple bound conformations

Based on the changes in chemical shift between free and bound states, the residues in the ACD that are the most significantly impacted by IxI/V binding are clustered in and near the $\beta_4/\beta_8$ groove, and exhibit slow chemical exchange (Fig 3D and E). Over the course of a titration, intensity from these resonances is lost and then re-appears in locations corresponding to the bound state. Using the software TITAN, which is capable of simultaneously analyzing the residues in both exchange regimes (Waudby et al, 2016), we determined $K_d$s of 132 µM for WT and 1,285 µM for P182L (Appendix Fig S5A–D, Appendix Table S2). These values are very close to those obtained from the CSP analysis of only the fast-exchanging residues and reinforce how the affinities of WT and P182L peptides for the ACD differ by an order of magnitude.

At high peptide concentrations, where, according to our $K_d$ measurements, we would expect the bound state to be almost exclusively populated, we noticed that the observed signal intensities for the slow-exchanging resonances were unexpectedly low and the fitted $R_2$ values of the bound state by TITAN extremely large (Appendix Fig S6A). These observations suggest that the “bound” state itself undergoes chemical exchange with a third, previously unidentified, conformational state in which the peptide is also bound. To test this hypothesis, we obtained 2D NMR spectra of the ACD in the presence of a 10-fold molar excess of peptide.
as a function of increasing temperature from 25 to 50°C. By increasing the temperature, the rate of interconversion between the two bound forms will increase, and we should see the reappearance of signals for the broadened resonances. Indeed, at elevated temperatures, signal intensity for the bound state began to recover to the expected levels (Appendix Figs S6B and S7B and C). These results reveal an unexpected and interesting detail in the binding of peptides with the ACD domain: in addition to a free and an initial bound state, a further bound state becomes populated at high peptide concentrations.

The P182L IxI/V motif binds with an attenuated association rate

To determine the origin of the weakened binding interaction in the P182L variant, we turned to Carr–Purcell–Meiboom–Gill (CPMG) relaxation dispersion (RD) (Palmer et al, 2001; Sugase et al, 2007b; Hansen et al, 2008b; Baldwin & Kay, 2009; Demers & Mittermaier, 2009). CPMG RD experiments can simultaneously probe the kinetics (association and dissociation rate constants; \(k_{\text{off}}, k_{\text{on}}\)), thermodynamics (populations of the interconverting states), and structural changes (differences in chemical shifts; \(|\Delta \omega|\)) involved in the interconversion between the principally populated ground state and a sparsely populated, conformationally excited state, whose fractional population is on the order of a few percent (Palmer et al, 2001; Sugase et al, 2007b; Hansen et al, 2008a, 2008b).

We interrogated peptide binding kinetics and thermodynamics with \(^{15}\text{N}\) CPMG RD experiments on the isotopically labeled ACD in the presence of unlabeled WT or P182L peptide. This experiment probes the \(^{15}\text{N}\) transverse relaxation rate (\(R_{2,\text{eff}}\)) as a function of the number of 180° refocusing pulses (\(\nu_{\text{CPMG}}\)), and variations in \(R_{2,\text{eff}}\) are indicative of millisecond conformational exchange between two or more states. In the absence of peptide, resonances in the \(\beta_4/\beta_8\) groove resonances showed no variation in \(R_{2,\text{eff}}\) with the refocusing pulse frequency (Appendix Fig S8A

![Figure 3. The P182L mutation diminishes the affinity of the IxI/V motif for cHSP27.](image-url)
and B). Adding a small amount of WT peptide (ca. 2% ACD-peptide complex), however, led to large variations in $K_{2,\text{eff}}$ with the refocusing pulse frequency, which are indicative of conformational exchange on the millisecond timescale (Fig 4A and B, Appendix Figs S8A and B, and S9A). The magnitude of the effect depended approximately linearly on the amount of added peptide (Appendix Fig S9B and C), which revealed that the conformational exchange event is intermolecular and the experiment effectively monitors peptide binding. Similar data were obtained for the P182L peptide-ACD complex (Fig 4A and B, Appendix Figs S8B and S9D and E), albeit with more peptide required to achieve a similar effect, further supporting the notion that the P182L peptide binds with lower affinity than the WT peptide (Fig 3C). The residues that yield dispersions are largely within 4 Å of the peptide in the bound state, based on the crystal structure of the peptide-bound ACD (Appendix Fig S8C and D).

To extract kinetic and structural information about peptide binding, we fit the CPMG RD data that were recorded at two static magnetic field strengths initially using a naïve two-state model. This model assumes interconversion between a free (unbound) and peptide-bound form of the ACD. The $^{15}$N $\Delta\omega$ values obtained from CPMG RD show that similar ACD regions experienced conformational exchange in both peptide-bound states (Fig 4C, ii, iii., Appendix Figs S8A and B, and S9A). Moreover, the fitted $^{15}$N $\Delta\omega$ values were highly similar for both the WT and P182L peptides, indicating that the peptides bind in a similar mode to the same site on the ACD (Appendix Fig S10, Appendix Table S1), as expected from the titration data (Fig 3D and E). The fitted $\Delta\omega$ values from the CPMG experiments on samples with a bound state populated to ca. 2% were consistent with the chemical shift changes observed more directly in the titration data (Appendix Fig S6B–E) suggesting that the CPMG RD and HSQC experiments were detecting the same end state. The fitted values for $K_{\text{eff}}$ were very similar for P182L and WT peptides, at $610 \pm 39$/s and $515 \pm 53$/s, respectively (Fig 4C i). This points toward the origin of the reduced binding affinity displayed by P182L deriving from an attenuated association rate.

While the observed chemical shift changes between free and bound states observed in the CPMG and titration experiments were quantitatively consistent, we noted a discrepancy between the measured $K_{d,s}$. In the CPMG and titration analyses, respectively, we obtained values of $1,762 \pm 120$ and $124 \pm 13$ μM for the WT $K_{d}$, and $8,373 \pm 534$ μM and $1,030 \pm 118$ μM for the P182L $K_{d}$ (Appendix Table S2). The ΔΔG values, between WT and mutant, are highly consistent when measured using either the CPMG or titration approach, but the absolute values vary by roughly an order of magnitude. To account for this, we noted that our titration analysis had already revealed the existence of (at least) 3 conformational states, and that upon addition of peptide, we can infer the presence of at least two bound states from the significantly increased observed $R_{2}$ values of residues in the vicinity of the β4/β8 groove. When analyzing CPMG RD data, it is common to assume that the $R_{2}$ values of the two states are identical (Palmer et al., 2001). However, in certain situations (Hansen et al., 2009; Baldwin et al., 2012), failing to account for differences in the $R_{2}$ rates can lead to incorrectly fitted values of $p_{0}$ (Ishima & Torchia, 2006). To avoid this possibility, we constrained our two-state CPMG analysis fit by enforcing the $K_{d}$ values to match those observed in the titration, and allowed the $R_{2}$ of the bound state to be a free parameter. The quality of the resulting fits we obtained was excellent, resulting in slightly lowered reduced $\chi^{2}$ values over the naïve analysis where $R_{2,\text{unbound}} = R_{2,\text{bound}}$. Notably, the fitted $\Delta\omega$ values were essentially unchanged in the two different analysis methods (Appendix Fig S11), indicating that the CPMG and titration data are in quantitative agreement (Appendix Fig S11). This result demonstrates that, for the residues in the vicinity of the β4/β8 groove, the bound state is undergoing conformational exchange on an “intermediate” timescale under these conditions. Our observations lend insight into the mechanism by which P182L has a lowered affinity versus the WT peptide for the ACD: when comparing the on and off rates determined by CPMG and the titration, in all forms of analysis, the larger difference is in the on rate (Appendix Tables S2 and S3).

The P182L IxI/V motif samples a larger range of conformational space

To understand the mechanistic basis of the slower on rate of the P182L peptide, we hypothesized that the rigid Pro residue in the unbound WT IxI/V motif would restrict overall flexibility of the adjacent Ile and Val residues, thereby pre-arranging the IxI/V motif for facile binding to the ACD. By contrast, the P182L mutation would remove the torsional constraints imposed by the restrictive Pro side chain and enable easier exploration of the accessible conformational space.

To test these hypotheses, we performed 200 ns of all-atom molecular dynamics (MD) simulations on peptides of the same compositions used for the NMR binding experiments (Fig 4D and E). The $\phi$ and $\psi$ dihedral angles of P182 (WT) or L182 (P182L) directly impact the conformation of the adjacent I181 and V183 residues within the IxI/V motif. We computed the free energy landscape for both the WT and P182L peptides as a function of $\phi$ and $\psi$ dihedral angles for P182 or L182 (Fig 4D). As expected, the analysis revealed that the central Pro residue in the WT IxI/V motif significantly limits the sampling of backbone $\phi$ and $\psi$ dihedral angles to a narrow region in Ramachandran space (Fig 4D). Notably, the conformation of the bound state of the IxI/V motif, as determined by X-ray crystallography (Hochberg et al., 2014), exhibits similar P182 $\phi$/$\psi$ angles (Fig 4D). By contrast, the P182L variant explores a much larger area of Ramachandran space (Fig 4D), and some of the other P182L conformers no longer adopt the necessary conformation for binding to the β4/β8 groove of the ACD. For example, near $\psi < 50^\circ$–$50^\circ$, large rotations about the I181 CO–P182 N and P182 CO–V183 CA bonds have moved the side chains of I181 and V183 out of plane (Fig 4D), which would sterically clash with the atoms in the β4/β8 groove.

In addition to a comparison of the $\phi$/$\psi$ dihedral angles about the P182 or L182 residue, we performed a principal component analysis (PCA) over the MD trajectories to capture variations between the predominant structural and dynamical features of the two peptides. The conformations of the WT peptide predominantly occupy two clusters in the space of the first and second principal components (Fig 4E), whereas the P182L variant instead shows a markedly broader distribution (Fig 4E). The larger spread in the PC space of the P182L peptide reflects a broader sampling of conformational space (Fig 4E). Our results indicate that one effect of the P182L mutation is an increase in conformational flexibility, which causes

© 2021 The Authors

The EMBO Journal  40: e103811 | 2021 7 of 23
et al, bound with higher affinity to the P182L variant of HSP27 (Geuens proteins, such as the poly C-binding protein 1 (PCBP1) which mutation also changes the affinities of its interactions with other ing of its own IxI/V motif. In addition, it is known that the P182L assemble into significantly larger oligomers by disrupting the bind-

Our results demonstrate that the P182L mutation causes HSP27 to its effect on binding between HSP27 and other IxI/V-containing proteins will be more accessible to IxI/V-containing proteins, we hypothesized that interactions between HSP27 and other IxI/V-containing proteins will be effectively strengthened.

the IxI/V motif to less frequently adopt the conformation required to bind to the hydrophobic [4/8]β8 groove.

**HSP27 interactors with IxI/V motifs bind with higher affinity to the P182L variant**

Our results demonstrate that the P182L mutation causes HSP27 to assemble into significantly larger oligomers by disrupting the binding of its own IxI/V motif. In addition, it is known that the P182L mutation also changes the affinities of its interactions with other proteins, such as the poly C-binding protein 1 (PCBP1) which bound with higher affinity to the P182L variant of HSP27 (Geuens et al, 2017). We note that PCBP1 contains multiple IxI/V motifs and therefore could compete with the IxI/V in HSP27 for binding to its [4/8]β8 groove (Hilton et al, 2013b). Since our data demonstrate that the IxI/V-binding site in P182L would be more accessible to IxI/V-containing proteins, we hypothesized that interactions between HSP27 and other IxI/V-containing proteins will be effectively strengthened.

To test this hypothesis, we first searched the human proteome for all instances of the IxI/V SLiM according to its traditional definition of [V/I]x[V/I] and then determined how many of these proteins overlapped with previously identified HSP27-binding proteins. The human proteome search yielded a total of 128,604 instances or 1.1% of all tripeptides (Appendix Table S4, Appendix Fig S12A and B). Next, we limited our search to the disordered regions of the proteome, because an IxI/V motif would need to be accessible in order to bind to the ACD, and SLiMs typically occur in unstructured regions of proteins (Davey et al, 2012). This reduced the number of [V/I]x[V/I] motifs by ca. 12-fold to 15,643 (Appendix Table S4, Appendix Fig S12A and B). Differences between the frequencies of [V/I]x[V/I] motifs in disordered and structured regions provide further insight into the amino acids that are enriched in these [V/I]x [V/I] motifs (Fig 5A, Appendix Fig S12C). The largest enrichment in disordered [V/I]x[V/I] motifs is found for x = proline (+6.7%), whereas the largest depletion is observed for x = leucine (–4.1%) (Fig 5A, Appendix Fig S12C). While proline is a disorder-promoting amino acid that is enriched in disordered regions (Theillet et al,
we note that our bioinformatics analyses here focus specifically on the nature of the amino acid between the Val or Ile residues within a [V/I]x[V/I] motif. Statistical tests reveal that a specific enrichment of Pro within [V/I]x[V/I] motifs is not simply due to the underlying amino acid frequencies (Appendix Fig S12D). These results demonstrate that, in disordered regions, proline-containing [V/I]x[V/I] SLiMs are the most abundant type. This suggests that, in the crowded intracellular environment, HSP27 will be exposed to many [V/I]x[V/I] motifs from different proteins that can compete for binding to the ACD.

Next, we computed the intersection of known HSP27-binding proteins (Stark et al., 2006) and proteins that contain a [V/I]x[V/I] SLIM (Appendix Fig S12E). Of the known 449 HSP27-binding proteins, a total of 22 proteins contain [V/I]x[V/I] SLIMs in disordered regions (Appendix Fig S12E, Appendix Table S5). Some of the identified proteins contain multiple such motifs in their primary sequences (Appendix Fig S12E, Appendix Table S5), which could further enhance their binding affinity to the P182L variant of HSP27 through multi-dentate interactions. To directly test whether P182L HSP27 binds with higher affinity to IxI/V-containing proteins, we reanalyzed a comparative HSP27 interactomics dataset (Haidar et al., 2019), in which V5-epitope-tagged P182L was immunoprecipitated from HeLa cells and statistically enriched interactors were identified by LC-MS/MS (Fig 5B). Of the 11 proteins that were specifically enriched in the P182L dataset, eight of these proteins contained [V/I]x[V/I] motifs (Fig 5B).

To validate these interactions, we used co-immunoprecipitation assays that enable determination of the enrichment with the P182L variant versus the WT protein. We pulled down V5 epitrone-tagged WT or P182L HSP27 and blotted for five different proteins (UBXN1, PCBP1, HSPB5, FAM83D, BAG3) (Fig 5C and D). For each target, we found that P182L pulled down an appreciably larger fraction than WT HSP27 (Fig 5C and D), indicating that these proteins bind to P182L with significantly higher affinity. WT HSP27 was unable to pull down UBXN1, PCBP1, or FAM83D, which suggests that these interactions are either specific to the P182L mutant or too labile with WT to be captured with this method. In an earlier study on PCBP1 (Geuens et al., 2017), we showed that WT HSP27 does interact with PCBP1, but found that this interaction was not straightforward to identify with co-immunoprecipitation assays. This suggests that WT HSP27 might also interact with UBXN1 and FAM83D in a transient manner, while the significantly tighter interactions with P182L could sequester these proteins away from their other binding partners.

We then sought to confirm that these tighter interactions between P182L and its IxI/V-motif-bearing interactors actually depend on the IxI/V motif. The co-chaperone BAG3 contains two IxI/V motifs in its N-terminus (Fig 5E), and previous work has indicated that BAG3 binds to shSPs, including HSP27, via these IxI/V motifs (Carra et al., 2008; Fuchs et al., 2010; Rauch et al., 2017). Given the increased availability of the IxI/V-binding site in the ACD of P182L HSP27 and the enrichment in IxI/V motifs in P182L interactors noted above, we reasoned that mutating both IxI/V motifs in BAG3 would abrogate the P182L-BAG3 interaction. Indeed, we created a BAG3 mutant in which both IPV motifs were mutated to GPG (BAG3-IPV mutant) and observed that it lost its interaction with the P182L variant (Fig 5E, Appendix Fig S13A and B). These findings suggest that IxI/V-containing proteins, at least in part, use these motifs to bind more tightly to the P182L variant.

Finally, we asked whether the more accessible IxI/V-binding site in P182L is responsible for the higher affinity interactions with these targets. We hypothesized that mutating the β4/β8 groove of P182L to prevent IxI/V binding would abolish interactions with IxI/V-containing proteins. To this end, we introduced the S155Q mutation that prevents IxI/V binding (Delbecq et al., 2012; Baughman et al., 2020) into the P182L variant (S155Q/P182L). We pulled down V5 epitope-tagged S155Q/P182L and blotted for the same interactors as above. We found that the double mutant S155Q/P182L was either completely unable to pull down the interactors (UBXN1, PCBP1, or FAM83D) or pulled down a much lower amount relative to P182L (BAG3 and HSPB5) (Fig 5F), suggesting that the β4/β8 groove comprises the primary interaction site for these targets. Collectively, our results demonstrate that IxI/V-containing proteins bind with higher affinity to the P182L variant of HSP27 via the more available β4/β8 groove.

Discussion

We have investigated the biophysical and functional impact of the CMT disease-causing P182L mutation in the highly conserved IxI/V motif of the intrinsically disordered CTR of HSP27. We found that the clinically severe P182L variant of HSP27 displays reduced chaperone activity and exists in a significantly larger oligomeric form both in vitro and in vivo, including within CMT patient-derived iPSC motor neurons. To our knowledge, the P182L variant of HSP27 assembles into the largest soluble sHSP oligomers observed thus far, surpassing E. coli IbpB (2–3 MDa) (Strozlecka et al., 2012). In addition, the P182L variant forms significantly larger oligomers than any of the CMT-related mutants of HSP27 studied to date across the entire polypeptide sequence (Chalova et al., 2014; Muranova et al., 2015; Weeks et al., 2018). Our in vitro experiments made use of purified proteins, indicating that the large P182L oligomers can be comprised solely of the mutant protein; however, while we observe qualitative agreement with the in vitro data, our in cellulo data cannot rule out that other components, in addition to WT HSP27 (Appendix Fig S3), might be present within the large P182L oligomers.

Because the structural basis for the dysregulation of HSP27 by the P182L mutation has remained unknown, we sought to provide atomic-level details regarding the impact of this single point mutation. To this end, we used NMR spectroscopy to compare the binding of the WT and P182L IxI/V motifs to the ACD of HSP27. Importantly, recent NMR data have demonstrated that the isolated ACD adopts a similar conformation to that observed in the full-length protein (Clouser et al., 2019), suggesting that the ACD provides a convenient system to investigate IxI/V binding. Our NMR data on the ACD (Figs 3 and 4) revealed a lowered association rate constant and hence affinity of P182L IxI/V binding to the ACD. A reasonable explanation for this decreased association rate constant is provided by our MD simulations (Fig 4), which show that Pro182 restricts the conformational landscape of the IxI/V motif, thereby placing it in a binding-competent conformation more often than the P182L variant. The larger sampling of conformational space by the P182L variant and larger loss of conformational entropy upon binding could thus contribute to its slower association rate constant (Pritišanac et al., 2019). However, we note that other
factors also regulate biomolecular interactions, including solvation, electrostatics, and hydrogen bonding propensity (Schreiber et al, 2009), and the rigidity imparted by Pro182 may be just one contributing factor. For example, it was shown that introducing polar interactions downstream of the IxI/V motif (F185H) can increase the binding affinity (Freilich et al, 2018), perhaps by establishing a new hydrogen bond between the H185 side chain and the P150 carbonyl (Appendix Fig S14). Thus, amino acids outside of the IxI/V motif can also contribute to this interaction. In addition, van der Waals contacts between the side chains of I181le and V183Val in

![Figure 5](image-url)
the IxI/V motif and the hydrophobic β4/β8 groove are critical for binding as substitution of the Ile and Val side chains with Gly completely disrupted the binding of an IxI/V-bearing peptide (Rauch et al., 2017).

The complex binding mechanism of the IxI/V motif is underscored by our observation that there are at least two interconverting bound states (Appendix Figs S6A and B, S7A and S11). The interconversion between multiple bound forms has previously been identified in other protein–protein interaction mechanisms, including those that involve the association of an intrinsically disordered region and a structured domain (Sugase et al., 2007a; Schneider et al., 2015; Delaforgé et al., 2018), including sHSPs (Delbecq et al., 2012; Clouser et al., 2019). In our case, the intrinsically disordered CTR of HSP27 docks into the β4/β8 groove of the structured ACD. Our identification of more than one conformation of the ACD-bound IxI/V suggests that this region binds in a dynamic manner.

We note that our observation of more than one bound state is consistent with the binding mechanism of the IxI/V motif in the related shSP αβ-crystallin, for which it was shown that the peptide-bound form exists in up to three different conformations (Delbecq et al., 2012). We have established previously that the affinity for binding the second peptide to the dimer is lower than the affinity for the first (Hilton et al., 2013a) which acts to control assembly and disassembly in the context of the full-length αβ-crystallin oligomers (Baldwin et al., 2011, 2012; Hochberg & Benesch, 2014). Thus, the IxI/V motif exhibits considerable motions in its free state, where it is intrinsically disordered, as well as in its bound state via the access of multiple interconverting conformations that quite possibly regulate assembly in HSP27, and shSPs more generally.

The P182L mutation lowers the binding affinity of the IxI/V motif for the β4/β8 groove and dysregulates oligomeric assembly. If the P182L variant decreases the overall binding affinity for the IxI/V motif, how does the full-length protein form larger oligomers than the WT protein? Studies on the related α-crystallin shSPs provide a rationale. In αβ-crystallin, the IxI/V motif, despite its proximity to the β4/β8 groove (Jehle et al., 2010; Baldwin et al., 2011), is nevertheless predominantly unbound in WT oligomers with ca. 1% of the CTDs being bound under physiological solution conditions and temperature (Baldwin et al., 2011, 2012). In αA-crystallin, a recent cryoEM study found few inter-ACD contacts; 70–80% of the subunits bound the IxI/V intramolecularly (Kaiser et al., 2019), consistent with an earlier crystal structure (Laganowsky & Eisenberg, 2010). In solution, the concomitant binding of two IxI/V motif interacts precipitates ejection of a monomeric subunit from the oligomer from αβ-crystallin (Baldwin et al., 2011, 2012). If a similar process governs the oligomerization of HSP27, we would expect a slower on rate of the IxI/V to lead to slower ejection of monomers from the oligomers, and so, the oligomeric size would increase (Baldwin et al., 2011, 2012), in line with our observations of P182L.

In addition to the CTD, the NTD is also known to play an important role in facilitating oligomerization in a range of sHSPs (Kaiser et al., 2019). For HSP27 specifically, WT-like oligomerization has been observed for CTR-truncated forms of HSP27 but not NTD-truncated forms (Lei-Garolla & Mauk, 2012). Recent studies of HSP27 oligomeric assembly identified interactions between specific regions in the largely disordered NTD (e.g., 5VFpK and Val85) and the IxI/V-binding site in the β4/β8 groove (Clouser et al., 2019; Collier et al., 2019), indicating that multiple regions of HSP27 compete for binding to the β4/β8 groove. Attenuating the binding affinity of the IxI/V motif in the CTR could enable other sites in the NTD to bind more frequently and hence significantly alter the oligomeric assembly landscape of HSP27 (Clouser et al., 2019; Collier et al., 2019).

Taken together, these results and our present work indicate a role for the CTR in regulating rather than underpinning oligomerization. Because the IxI/V motif can bind to the β4/β8 in an intra- or intermolecular manner (Kaiser et al., of the P182S variant, namely its assembly into2019) or are transiently bound (Baldwin et al., 2011), it may serve as the “gatekeeper” that regulates what binds to the β4/β8 groove (Hochberg & Benesch, 2014). Prior studies independently support such a role, as mutants in HSP27 that disrupt binding of its IxI/V motif have been shown to increase rather than decrease the molecular mass, including the CMT-causing mutation P182S (Chalova et al., 2014), the 181IPV183 to 181GPG183 variant (Freilich et al., 2018), and other IxI/V mutations (Pasta et al., 2004; Hilton et al., 2013a; Freilich et al., 2018). The behavior of the P182S variant, specifically its assembly into a significantly larger oligomeric form than the WT protein, suggests that the P182S mutation acts similarly

---

**Figure S5. The P182L variant binds with enhanced affinity to IxI/V-containing proteins.**

A Percentage of [IxI]x[V] tripeptides among (top) the total number of all tripeptides (% tripeptides) or (middle) the total number of [IxI][x][I/V] tripeptides in the (B) bound or disordered regions (red) [IxI][x][V] % shown as a function of the X residue type. (Bottom) The difference between [IxI][x][I/V] % for disordered and structured regions shows the enrichment (positive) or depletion (negative) of specific [IxI][x][I/V] motifs in disordered regions. The gray bars indicate the [IxI][x][I/V] and [IxI][P][x][I/V] motifs studied in this work, i.e., IxI and IPV.

B Volcano plot representing the interactors that are enriched for the P182L mutant versus GFP as a negative control, obtained with affinity-enrichment mass spectrometry. Proteins that co-immunoprecipitated significantly more (p < 0.05) with the P182L variant are shown in the upper right quadrant. Interactors with one or more [IxI][x][V] motifs are displayed in red while not significantly enriched interactors are displayed in black.

C, D Co-immunoprecipitation from HeLa cells stably overexpressing V5-epitope-tagged HSP27 (WT or P182L mutant) using anti-V5 beads. Co-immunoprecipitation was quantified and presented as a percentage relative to the P182L variant (n = 3). The mean ± one standard deviation (n = 3) is shown. Right: the location of Pro182 (red) in the crystal structure of peptide-bound chHSP27 (PDB: 4mjh) and in silico creation of the P182L mutation (blue). The peptide is shown in white sticks. P182L specifically weakens binding of the HSP27 IxI/V motif.

E Co-immunoprecipitation from HeLa cells stably overexpressing V5-epitope-tagged HSP27 (WT or P182L mutant) and transiently transfected with BAG3-eCFP (WT or IPV-mutant) using anti-CFP beads. Western blots for anti-CFP (BAG3), V5 (HSV81), and α-tubulin. NS indicates a non-specific band. Note that detection of BAG3 (anti-CFP) and HSP27 (anti-V5) occurs with different antibodies. The locations of the IPV-to-GPG mutations in BAG3 are depicted below.

F Co-immunoprecipitation from HeLa cells transiently transfected with V5-epitope-tagged HSP27 (P182L or S155Q/P182L mutant) using anti-V5 beads (n = 2). Right: the location of Ser155 (red) in the crystal structure of peptide-bound chHSP27 (PDB: 4mjh) and in silico creation of the S155Q mutation (purple) showing a clash with the bound peptide. The peptide is shown in white sticks. S155Q disrupts binding of all IxI/V motifs to HSP27.

Source data are available online for this figure.
as P182L by lowering the affinity for the β4/β8 groove (Chalova et al., 2014). In addition, the physiological O-GlcNAcylation of T184, which is immediately upstream of the 181IPV183 motif, disrupts binding of the IxI/V motif and increases the average HSP27 oligomer size to > 1 MDa (Balana et al., 2019), indicating regulation of Ix/V binding through post-translational modification. Given the universal nature of the Ix/V motif in sHSPs, we speculate that evolution has finely tuned its affinity for the ACD to optimally balance the binding of self versus others, thereby influencing oligomerization and chaperone activity. It will be of interest to assess how mutations that increase the affinity of the Ix/V motif will affect the properties of HSP27; for example, the F185H mutation significantly lowered the $K_d$ of peptide binding (Freilich et al., 2018).

Dysregulated binding of the NTD to the β4/β8 groove could have implications for the chaperone mechanism of HSP27, as recent NMR data have indicated that aggregation-prone substrates can either bind to the NTD, the ACD, or the β4/β8 groove (Mainz et al., 2015; Freilich et al., 2018; Baughman et al., 2020; Liu et al., 2018, 2020), and HSP27-substrate interactions involving the β4/β8 groove may not always prevent substrate aggregation (Baughman et al., 2020). For such substrates that interact with the β4/β8 groove, the binding affinities appear to be very weak (Baughman et al., 2018; Freilich et al., 2018; Liu et al., 2018, 2020), and these interactions would exist in competition with binding of the Ix/V motif. Therefore, increased availability of the β4/β8 groove in P182L Ix/V would leave its β4/β8 groove more accessible to interactions with other inter- and intramolecular contacts and could reduce the number of NTD-substrate interactions and decrease the overall chaperone activity of the HSP27 chaperone. At least for the substrate tau, it was shown that the NTD is required to prevent substrate aggregation, whereas binding of tau to the β4/β8 groove does not prevent substrate aggregation (Baughman et al., 2020).

As another consequence, an interacting partner may become dysregulated due to aberrant interactions with P182L that disrupt other interaction networks. A previous study found that competing interactions between HSP27 self-binding and substrate binding regulated HSP27 function and oligomerization (Freilich et al., 2018). For five different Ix/V-containing proteins (UBXN1, PCBP1, HSPB5, FAM83D, and BAG3), our co-immunoprecipitation data demonstrate that they all bind more tightly to the β4/β8 groove than WT HSP27. We also showed that disruption of the β4/β8 groove in P182L via the S155Q mutation prevents these interactions (Fig 5) and that, for BAG3, the interaction with P182L depends on its own IPV motifs (Fig 5). Notably, WT HSP27 was unable to pull down three of these interactors (UBXN1, PCBP1, and FAM83D), which suggests that they may only transiently associate with the WT protein via the β4/β8 groove. By increasing the affinity of these interactions via the P182L mutation, however, we were able to clearly identify these targets as interactors. Bioinformatic identification of proteins that harbor [V/I]P[V/I] SLiMs may help instead to identify targets that are not known HSP27 interactors but could potentially bind to HSP27 via weak, transient interactions with the β4/β8 groove.

The disrupted interaction network caused by the P182L mutation most strongly impacts WT HSP27 itself. Mutations in HSP27 that cause CMT disease and dHMN, including P182L and P182S, are generally autosomal dominant, meaning that one allele will contain the mutated form of the gene and the other allele will contain the WT gene. Assuming relatively equal levels of expression in vivo, a mixed population of WT and P182L HSP27 will be present inside the cell and hetero-oligomers of varying ratios of WT:P182L will presumably exist, as has been established for other disease-causing variants of HSP27 in vitro (Nefedova et al., 2013). Indeed, we demonstrated here that P182L and WT HSP27 hetero-oligomerize in vitro and inside HeLa cells (Appendix Fig S3). Therefore, the available cellular pool of WT HSP27 will not only be depleted by having just one allele from which it is expressed but also by the local sequestration of the WT protein by P182L oligomers.

Other interaction partners are also affected by the dysregulated interactions of P182L. For instance, we showed previously that sequestration by the P182L variant causes a loss of translational repression by the RNA-binding protein PCBP1 (Geuens et al., 2017). The BAG3/HSP27 co-chaperone/chaperone interaction, on the other hand, promotes new protein–protein interactions, in part by bringing together HSP27 with other BAG3-bound chaperones, including HSP70 (Rauch et al., 2017; Meister-Broekema et al., 2018). Moreover, BAG3 is recruited to stress granules via its interactions with HSPB8 where the BAG3-HSPB8-HSP70 complex plays a key role in ensuring stress granule functionality (Ganassi et al., 2016). Likewise, it has been shown that HSP27 is also recruited to stress granules (Ganassi et al., 2016; Jain et al., 2016) and that it plays a direct role in chaperoning proteins inside stress granules (Liu et al., 2020). Therefore, disturbing the dynamic balance of the HSP27-BAG3 interaction might therefore affect a wider chaperone network and contribute to destabilization of proteostasis (Merin et al., 2018). Notably, mutations in the BAG3 IPV motifs also contribute to human disease: a Pro-to-Leu mutation is implicated in myofibrillar myopathy (Selcen et al., 2008; Freilich et al., 2018; Meister-Broekema et al., 2018), and another Pro-to-Ser mutation is implicated in CMT disease (Shy et al., 2018; Adriaenssens et al., 2020). The P209L mutation in BAG3, which replaces one of the two IPV motifs with 209ILV210, lowered its binding affinity for HSP27 to the same degree as deleting that IPV motif (Meister-Broekema et al., 2018). The presence of disease-causing mutations in the Ix/V SLiMs of HSP27 and BAG3 suggests important roles for these motifs.

In summary, our results provide an unexpected mechanistic explanation for the consequences of a mutation in the conserved Ix/V motif, which causes a severe form of CMT. Namely, the P182L mutation makes the Ix/V-binding site of HSP27 more accessible for interactions with other Ix/V-bearing proteins, leading to higher affinity interactions with such proteins. Given the high level of conservation in the Ix/V motif across various mammalian sHSPs, we anticipate that our results will relate to other sHSP systems and implicate this motif as a key mediator of sHSP-target interactions.

### Materials and Methods

Peptides were synthesized by Biomatik with N-terminal acetylation and C-terminal amidation. The sequences of the WT and P182L peptides are $^{178}$EITIPVFE$^{185}$ and $^{178}$ETILYF$^{185}$. The peptides were dissolved in NMR buffer (30 mM sodium phosphate, 2 mM EDTA, pH 7), but the pH values of the solutions were found to be in the 4–5 range. Because cHSP27 is highly pH-sensitive (Clouzer & Klevit, 2017; Alderson et al., 2019, 2020), the pH of all peptide solutions was corrected to 7 using small volumes of concentrated NaOH.
Protein samples for NMR, chaperone activity assays, CD, negative-stain EM, and SEC-MALS were expressed in E. coli and purified as described previously (Alderson et al., 2019). WT HSP27 comprises residues 1–205, encompassing the entire amino acid sequence. The P182L mutation was introduced into the WT HSP27 expression plasmid via site-directed mutagenesis. The full-length P182L variant of HSP27 was expressed as the WT form but went into inclusion bodies, which were solubilized in 8 M urea, spun at 20,000 xg for 20 min, and then dialyzed into 30 mM sodium phosphate, 100 mM NaCl, 2 mM EDTA, and pH 7 buffer. The supernatant was filtered with a 0.22-µm filter and then loaded onto a Superdex 200 gel filtration column equilibrated in 30 mM sodium phosphate buffer, 100 mM NaCl, 2 mM EDTA at pH 7.

cHSP27 encompasses residues G84–K171 of HSP27, and the expression plasmid contains an N-terminal hexahistidine tag followed by a tobacco etch virus (TEV) protease cleavage site. The expression plasmid for cHSP27 was transformed into E. coli and expressed as described previously (Alderson et al., 2019). Following exchange into a buffer without reducing agent, cHSP27 forms an intermolecular disulfide bond involving C137 from adjacent subunits. The NMR buffer used was 30 mM sodium phosphate, 2 mM EDTA at pH 7 with 6% D2O added for the lock. For NMR titration and relaxation dispersion studies, this disulfide bond was left intact to minimize contributions from exchange between the monomer and dimer. The formation of the disulfide bond is readily identifiable in the 2D 1H-15N HSQC spectra of 15N-cHSP27 via the resonances from R136 and C137; upon reduction or C137S mutation, these resonances become very weak or broaden into the noise (Rajagopal et al., 2015; Alderson et al., 2019). In addition, the oxidized dimer simplifies the analysis of titration and CPMG RD data, as only a single state of the protein is present, rather than a mixture of two forms (non-covalent dimer and monomer).

**Chaperone activity assays**

Chaperone activity assays were completed in triplicate, with the mean and one standard deviation reported. Assays were performed using a 96-well plate and a FLUOstar Omega Microplate Reader or Tecan Infinite M200 PRO plate reader. The substrates were porcine heart MDH (Sigma-Aldrich) and human insulin (Sigma-Aldrich). MDH was prepared at 0.2 µM and was incubated at 40°C in 30 mM sodium phosphate, 100 mM NaCl, 2 mM EDTA at pH 7. The increase in absorbance at 340 nm was monitored over time in the absence and presence of 0.5 µM WT or P182L HSP27. The MDH aggregation assay proceeded for 3 h. Likewise, the aggregation of 40 µM insulin at 40°C in the same buffer as above was monitored by the increase in absorbance at 340 nm upon the addition of 1 mM DTT. Insulin aggregation reactions were monitored in the absence or presence of 20 µM WT or P182L HSP27, and the reactions proceeded for 0.5 h. Control experiments were performed using 20 µM WT or P182L HSP27 incubated alone in the same buffer as above at 40°C for 3 h. Chaperone activity (Appendix Fig S1) is defined as 1 – Θ, where Θ is the maximum absorbance for the chaperone plus substrate mixture divided by the maximum absorbance of the substrate alone. Values of 1 and 0, respectively, indicate maximum protection and the absence of protection against aggregation.

**SEC-MALS**

Molecular masses were estimated by analytical SEC with in-line MALS (DAWN Heleos-II, Wyatt Technology Inc., Santa Barbara, CA), refractive index (Optilab T-rEX, Wyatt Technology, Inc.), and UV detectors (Waters 2487, Waters Corp., Milford, MA), along with ASTRA version 6 software that was provided with the instrument.

To characterize the isolated proteins, 250 µg of each protein was injected to a pre-equilibrated Superdex-200 column (for P182L and HSP27) or Superdex-75 column (for cHSP27 with the C137S mutation) in 30 mM sodium phosphate, 100 mM NaCl, 2 mM EDTA buffer at pH 7 and eluted at a flow rate of 0.5 ml/min. The monomer concentration of WT and P182L HSP27 corresponded to 40 µM. The calculated molar masses of HSP27, P182L, and cHSP27 (C137S) were 470 kDa, 13,600 kDa, and 17.5 kDa, respectively, within 1–1.2% error. The theoretical mass of the cHSP27(C137S) dimer is 19.8 kDa, so the slightly lower value as determined by SEC-MALS likely reflects contributions from exchange with the free monomer. Note that the C137S mutation does not impact the overall structure of the cHSP27 dimer (Alderson et al., 2019). The molecular mass of WT HSP27 is in good agreement with previous studies (Joviccević et al., 2015; Mishra et al., 2018), with masses of 670 kDa obtained by analytical SEC and 400 kDa by SEC-MALS. The hydration radii of WT and P182L HSP27, as determined by SEC-MALS, are 9 and 38 nm, respectively.

For the hetero-oligomerization experiment, 250 µg of WT HSP27 was loaded onto a Superose 6 10/300 column in 20 mM sodium phosphate, 100 mM NaCl, 2 mM EDTA at pH 7. A second sample was then prepared in which 230 µg of WT HSP27 was mixed with 230 µg of the P182L variant, and this sample was equilibrated overnight at room temperature before injection onto the column.

**Negative-stain EM**

Samples for negative-stain EM were prepared at 4.5 µM monomer concentration in 30 mM sodium phosphate, 100 mM NaCl, 2 mM EDTA at pH 7. Samples were loaded onto carbon-coated copper EM grids (Ultrathin Carbon Film/Holey Carbon; Ted Pella) and incubated there for 60 s. Excess sample was blotted off the grid, and then, the grids were washed with deionized water and stained with 0.5% uranyl formate for 20 s. Excess stain was removed by blotting. Negative-stain EM images were then collected on a FEI Tecnai T12 electron microscope operating at 120 kV, which was equipped with a Gatan US1000 CCD camera.

**Cell lines, cell culture, and transfection**

HeLa cells were cultured in MEM medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific), 1% glutamine (Thermo Fisher Scientific), and 1% penicillin/streptomycin. Cells were maintained at 37°C and 5% CO2 atmosphere. To create HSP27 CRISPR knockout lines, we generated a sgRNA containing pSpCas9(BB)-2A-PURO (PX459) V2.0 vector (Addgene, #62988). The most specific sgRNA was selected with crispr.mit.edu by targeting the first exon of the HSPB1 gene. Through molecular cloning following Ran et al. (2013), the sgRNA was cloned into the BbsI restriction site and successful insertion was verified by Sanger sequencing. HeLa cells were seeded in a 6-well plate and

© 2021 The Authors
transiently transfected using polyethylenimine (PEI). After 24 h, the medium was supplemented by 1 µg/ml puromycin to select for positively transfected cells. The puromycin was removed after 72 h as all the cells were dead in a non-transfected well. The positively transfected cells were then serially diluted in a 96-well plate with an estimated 0.5 cells/well. Wells that contained clonal expansion for more than one colony were discarded. Other wells starting from a single colony were expanded and collected to verify the genome editing both at the protein and DNA level. Knockout clones were identified by Western blotting using a monoclonal HSP27 antibody (Enzo Life Sciences SPA-800). The successful clones were screened further by DNA sequencing of the edited genomic region, after subcloning the amplicons into pUC19 plasmids. This allowed to identify the genome edits for each of the respective alleles. Only clones with an identified stop codon on each allele were selected for further experiments.

For microscopy experiments, HSP27 knockout HeLa cells were grown on standard cover glasses (12 mm #1.5) at a concentration of 50,000 cells/well. The cells were transiently transfected with HSP27 wild-type or P182L mutant ORF in pLenti6/V5 plasmids (Thermo Fisher Scientific).

**Expansion microscopy sample preparation and imaging**

Cells were immunostained and processed for expansion microscopy employing a protocol by Chozinski et al (Chozinski et al, 2016). Twenty-four hours after transfection, cells were fixed for 20 min in 3.2% paraformaldehyde and 0.1% glutaraldehyde in PBS with 5-min reduction in borohydride. After three PBS washes, samples were blocked and permeabilized for 1 h at room temperature in normal goat serum (1:500, Dako) and 0.5% Triton X, dissolved in PBT buffer (PBS + 0.5% BSA + 0.02% Triton X). Primary antibody incubation over night at 4°C with 1:500 anti-HSP27 (Enzo Life Sciences SPA-800) in PBT was followed by four 5-min and one 30-min PBT washes, 1-h secondary antibody incubation at room temperature (1:500 in PBT, AlexaFluor488 goat anti-mouse, Thermo Fisher Scientific A11001), four 5-min PBT washes and one 30-min PBT wash. Control coverslips for conventional confocal microscopy were treated similarly, except for overnight incubation over night at 4°C in PBS with polymerization initiated with TEMED and APS.

Cytoplasmic regions of interest were randomly selected from image stacks (200 × 200 pixels, single slice), and the HSP27 distribution was analyzed using the Fiji distribution of ImageJ (Schindelin et al, 2012; Schneider et al, 2012). After noise filtering (Gaussian blur, sigma 0.7), high-intensity spots were detected with the Find Maxima tool (fixed noise level 50). The intensity and size of the spots were measured with the GaussFit_OnSpot plugin (Peter Haub and Tobias Meckel) using circle shape and Levenberg Marquardt fit mode and 10-pixel (850 nm) rectangle half size. All images were processed in batch using ImageJ macro scripts. Data analysis and plotting was done using R (R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2015). Misfitted spots were removed by excluding spots smaller than 20 nm and larger than 200 nm (FWHM in expansion microscopy corrected dimensions). For each genotype, 15 cytoplasmic regions of the same size as the expansion microscopy images in Fig 2C were analyzed (4 × 4 µm), which resulted in the detection of 3342 spots in total. Mean intensities of the entire images were measured using ImageJ, after background correction by subtraction of a Gaussian blurred image (500-pixel radius).

**Sucrose gradient assay**

HeLa cells were lentivirally transduced with HSPB1-V5 (wild type or P182L mutant) and collected for protein extraction with RIPA buffer (1% Nonidet P-40, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholic acid, 1 mM EDTA, 50 mM Tris–HCl pH 7.5, cComplete Protease Inhibitor Cocktail (Roche Applied Science, Indianapolis, IN, USA), Phospho-STOP inhibitor mix (05 892 970 001, Roche Applied Science, Indianapolis, IN, USA)] for 30 min on ice. Protein concentrations were quantified using BCA (23225, Pierce BCA Protein Assay Kit). The sucrose gradient was generated by diluting an 80% sucrose stock solution in PBS to 70, 60, 50, 40, 30, 20 and 10%. Equal amounts of each fraction were layered on top of each other and allowed to equilibrate on ice for 30 min. Equal amounts of protein lysate were then loaded on top of the gradient. Note that this is total whole cell protein lysate and thus contains both soluble and non-soluble proteins. Samples were centrifuged for 60 min at 55,000 rpm (164,025 g) in a TLA-110 rotor (Beckman). Nine samples were collected and prepared for SDS–PAGE analysis. After separation on 4–12% NuPAGE gels (Life Technologies, Carlsbad, CA, USA). Proteins were transferred to nitrocellulose membranes (Hybond-P; GE Healthcare, Wauwatosa, WI, USA) and decorated with antibodies against V5 (R96025, Invitrogen, Carlsbad, CA, USA). Samples were detected using enhanced chemiluminescent ECL Plus (Pierce, Life Technologies, Carlsbad, CA, USA) and LAS4000 (GE Healthcare, Wauwatosa, WI, USA). We note that, for both WT and P182L HSP27, two populations of oligomers are observed in the sucrose gradient assay, whereas only a single elution peak is obtained in the SEC-MALS experiments. Observation of a single elution peak by SEC-MALS, however, does not mean that only a single population of oligomers is present:

Image stacks of the expanded sample were acquired on a Zeiss LSM700 with Plan-Apochromat 63x/1.40 objective, using 85 × 85× 445 nm voxel dimensions (corresponding to approximately 20 × 20 × 100 nm in a non-expanded sample). We measured minimal spot diameters (FWHM in expansion corrected scales) in the range of 60–80 nm (data not shown), confirming that the physical size of the particles is still below this limit and cannot be directly quantified.
HSP27 and other sHSPs form a polydisperse ensemble of oligomers (Hochberg & Benesch, 2014), and gel filtration elution profiles reflect the ensemble-averaged nature of the sample. Moreover, our observation of two populations of oligomers by the sucrose gradient assay is consistent with analytical SEC performed as a function of HSP27 concentration (Jovevski et al., 2015). At high protein concentrations, only a single elution peak was observed, corresponding to large oligomers; decreasing the total protein concentration caused the dissociation of large oligomers into smaller species, accompanied by two elution peaks (Jovevski et al., 2015). Our SEC-MALS experiments were performed at an HSP27 concentration of 40 μM (monomer), which promotes formation of large oligomers and a single elution peak via gel filtration. By contrast, our sucrose gradient assays contained a significantly lower HSP27 concentration, thereby promoting the formation of small and large oligomers. Finally, the sucrose gradient assay detected HSP27 from mammalian cells that may phosphorylate HSP27 and cause elevated dissociation of oligomers. These orthogonal assays highlight the complex nature of HSP27’s oligomeric assembly, and no one technique can capture all aspects of this dynamic process on its own.

**Co-immunoprecipitation**

Stable HeLa cell lines for HSPB1-V5 (wild type or P182L mutant) were either untransfected and collected or transiently transfected with wild-type or IPV-mutant BAG3-GFP constructs using linear polyethylenimine (PEI) (Polysciences Europe, Hirschberg an der Bergstrasse, Germany) twenty-four hours before collection. The IPV-mutant of BAG3-GFP was generated by site-directed mutagenesis by replacing the first and second IPV motifs of BAG3 with GPG (the respective amino acids are 96–98 and 208–210). After collection, cells were lysed in lysis buffer (20 mM Tris–HCl pH 7.4, 2.5 mM MgCl₂, 100 mM KCl, 0.5% Nonidet P-40, Complete Protease inhibitor (Roche Applied Science, Indianapolis, IN, USA)) and incubated on ice for 30 min. Protein lysates were cleared by centrifugation for 10 min at 20,000 g at 4°C and washed three times with wash buffer [20 mM Tris–HCl pH 7.4, 2.5 mM MgCl₂, 100 mM KCl, Complete Protease inhibitor (Roche Applied Science, Indianapolis, IN, USA)]. Beads were supplemented with NuPAGE LDS sample buffer (Life Technologies, Carlsbad, CA, USA) and loaded on 4–12% NuPAGE gels (Life Technologies, Carlsbad, CA, USA). Samples were transferred to nitrocellulose membranes (Hybond-P; GE Healthcare, Wauwatosa, WI, USA) and decorated with antibodies against GFP (ab290, Abcam, Cambridge, UK), V5 (R96025, Invitrogen, Carlsbad, CA, USA), UBXN1 (16135-1-AP, Proteintech, Manchester, UK), PCBP1 (1G2, Novus Biologicals, Centennial, CO, USA), CYRAB/HSPB5 (MAB4849, R&D Systems, Minneapolis MN, USA), FAM83D (PA5-9901, Invitrogen, Carlsbad, CA, USA), BAG3 (10599-1-AP, Proteintech, Manchester, UK), GAPDH (GTX100118, GeneTex, Irvine, CA, USA), β-actin (A5441, Sigma-Aldrich, Saint Louis, MO, USA), or Tubulin (ab7291, Abcam, Cambridge, UK).

Detection of HSP27 monomer and dimers by Western blot

HeLa cells were seeded in a 6-well plate and transiently transfected using polyethyleneimine (PEI). After 24 h, the cells were collected for protein extraction by centrifugation and lysed in RIPA buffer [1% Nonidet P-40, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholic acid, 1 mM EDTA, 50 mM Tris–HCl pH 7.5, cComplete Protease Inhibitor Cocktail (Roche Applied Science, Indianapolis, IN, USA), PhosphoSTOP inhibitor mix (05 892 970 001, Roche Applied Science, Indianapolis, IN, USA)] for 30 min on ice. Protein concentrations were quantified using BCA (23225, Pierce BCA Protein Assay Kit). For detection of dimers, protein lysates were boiled for 5 min at 95°C in non-reducing NuPAGE LDS sample buffer (Life Technologies, Carlsbad, CA, USA). To dissociate the dimers into monomers, the sample buffer was complemented by 100 mM DTT prior to boiling. Both samples were loaded on the same SDS–PAGE gel and analyzed by Western blot as described above. HSP27 contains only a single cysteine residue (C137) and can form a disulfide bond across the ACD dimer interface.

**Interactomics for the P182L variant**

We reanalyzed a dataset that was previously published (Haidar et al., 2019). Label-free MS/MS was performed on co-immunoprecipitation samples obtained after mixing anti-V5 beads and protein lysates from HeLa cells overexpressing HSP27-P182L-V5 or GFP-V5. The data were analyzed as previously described, and the volcano plot in Fig 5 displays the P182L versus the GFP negative control datasets after a two-way ANOVA test to calculate the –log P-values. From this volcano plot, we verified which of the significantly enriched interactors contained an [I/V][I/V] motif.

**Generation of iPSCs from fibroblasts**

Primary human fibroblasts were obtained from skin biopsies of a CMT patient and a healthy control individual after informed consent and with the approval of the medical ethical committee of the University of Antwerp. The samples were obtained from a 29-year-old male patient who was diagnosed with the disease at the age of 5 years; the patient was first described in Evgrafov et al. (2004) and further clinical details can be obtained from Dierick et al. (2008). Human iPSCs were generated by the VIB Stem Cell Institute (Leuven, Belgium) according to a previously published protocol (Takahashi et al., 2007). In brief, the human iPSCs were generated from the patient-derived fibroblasts using the CytoTune-iPS 2.0 Sendai Reprogramming kit (A16517, Thermo Fisher Scientific) which contains the Yamanaka reprogramming factors (Klf4, Oct3/4, Sox2, and cMyc). All factors were transfected using non-integrating Sendai virus vectors. The clearance of Sendai virus was confirmed with the TaqMan iPSC Sendai Detection kit (A13640, Life Technologies). The iPSCs were validated for their pluripotency and for the presence of the disease-causing P182L mutation in HSPB1 using Sanger sequencing.

**Differentiation of motor neurons from iPSCs**

Differentiation of the iPSCs into motor neurons was performed using a previously published protocol (Guo et al., 2017; Haidar et al., 2019). Briefly, iPSCs were cultured on Matrigel matrix (354234,
VWR Technologies) and in Essential 8 flex medium with supplement (A285501, Life Technologies) and penicillin-streptomycin. To differentiate the iPSCs, the Essential 8 flex medium was replaced by Neuronal medium, consisting of Neurobasal medium (21103049, Life Technologies), DMEM/F12 medium (11320033, Life Technologies), B27 supplement without vitamin A (17504044, Life Technologies), GlutaMAX (35050061, Life Technologies), ascorbic acid (50-81-7, Sigma-Aldrich), and β-mercaptoethanol (31350010, Life Technologies). The dual SMAD inhibitors LDN (S2618, Selleck Chemicals) and SB (1614, Bio-technne) and the WNT antagonist CHIR (4423/10, Bio-technne) were added during the first 2 days. In the following days, we added the ensuing list of compounds to allow further differentiation and maturation of the motor neurons: retinoic acid (302-79-4, Sigma-Aldrich), smoothened agonist (SAG, 4366/1, Bio-Techne), and ciliary neurotrophic factor (GDNF, Immunosource), glial cell-derived neurotrophic factor GDNF inhibitor (DAPT, 2634/10, Bio-Techne), and the neurotrophic factors brain-derived neurotrophic factor BDNF (CSB-EL016134MO, Immunosource), glial cell-derived neurotrophic factor GDNF (21-8506-U002, Immunosource), and ciliary neurotrophic factor (CNTF, 21-7028-U005, Immunosource). Motor neurons were replated at 1 x 10^6 cells/ml in laminin-coated wells (Sigma-Aldrich). Additionally, to enhance the purity of the neuronal cultures, a single treatment of 1 µM ARA-C (cytotoxic β-D-arabinofuranoside, Sigma-Aldrich) was applied after re-plating on day 14. From day 18 onwards, the cells were cultured in this motor neuron maturation medium (containing BDNF, GDNF, and CNTF), and the media was changed every other day by replacing half of the medium.

The differentiated motor neurons were fixed on day 37 in 4% paraformaldehyde (Sigma-Aldrich) for 20 min at room temperature. After fixation, cells were permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) in PBS and blocked with 5% bovine serum albumin (BSA, Sigma-Aldrich) for 1 h. Cells were subsequently incubated with primary mouse monoclonal anti-HSPB1 (SPA-800, Enzo Life Sciences) and secondary AlexaFluor donkey-anti-mouse 488 antibody (Life Technologies). The nucleus was stained with Hoechst 33342 (Life Technologies). Cells were imaged with a Zeiss LSM700 laser scanning confocal microscope using a 40×/1.3 Plan-NeoFluar objective. Image analysis was done in the Fiji distribution of ImageJ (Schindelin et al., 2012; Schneider et al., 2012).

NMR spectroscopy

All NMR spectra were recorded on a 14.1-T (600 MHz 1H Larmor frequency) Varian Inova spectrometer equipped with a 5 mm z-axis gradient, room temperature probe. All NMR data were acquired with NMRPipe (Delaglio et al., 1995) and visualized with NMRFAM-Sparky (Lee et al., 2015). For quantitative purposes, peak shapes were fit with FuDA (Vallurupalli et al., 2008). For the WT and P182L peptides, 1D 1H NMR spectra were recorded at 25°C. The samples were prepared by dissolving natural-abundance peptides at a concentration of 2 mM in 30 mM sodium phosphate, 2 mM EDTA at pH 7 with 6% D2O added to maintain lock. Spectra were recorded with 64 scans, a maximum acquisition time of 1 s, and an interscan delay of 1.5 s for a total duration of 2.7 min.

For the titration of 15N-chSP27 with unlabeled peptides, sensitivity-enhanced 2D 1H-15N HSQC spectra (Kay et al., 1992) were collected with 128 x 512 complex points in t1 x t2 with maximum acquisition times of 71 and 64 ms, respectively. A new sample was prepared for each titration point using the same stock solutions of 15N-chSP27 and peptide, which avoids the need to account for sample dilution during the titration. Eight scans were collected per FID with a 1-s interscan delay, leading to a duration of 38.7 min per spectrum. Backbone resonance assignments of chSP27 were performed previously (Alderson et al., 2019) and are available under BMRB accession code 27046. The titrations in Fig 3 were performed at 25°C, and the 10:1 peptide:chSP27 sample was then used to record spectra from 25 to 50°C in 5°C increments (Appendix Fig S6B). To calculate the combined, weighted backbone amide CSPs for 15N-chSP27 in the presence of increasing amounts of WT and P182L peptides, we used the following equation:

$$\Delta \delta = \sqrt{(\Delta H)^2 + (0.2 \Delta N)^2}$$

where ΔH and ΔN are the differences in 1H and 15N chemical shifts extracted from 2D 1H,15N HSQC spectra of 15N-chSP27 in the presence and absence of peptides. The factor of 0.2 that precedes ΔN accounts for the larger range of chemical shifts populated by the 15N backbone amide. To determine the Kd values for WT and P182L peptide binding to the ACD, we fit CSPs from resonances that were in fast exchange to the following equation:

$$\Delta \delta = \Delta \delta_{\text{max}} \frac{([P] + [L] + K_d) - \sqrt{([P] + [L] + K_d)^2 - 4[P][L]}}{2[P]}$$

where Δδ is the measured CSP at a given peptide concentration, Δδmax is the maximum CSP observed, [P] is the total protein concentration, [L] is the total added ligand (peptide), and Kd is the fitted dissociation constant. This equation assumes a two-state binding interaction, and the high-quality of the fits of the NMR data to a two-state model suggests that two IxI/V-containing peptides bind concurrently to the ACD dimer in the following manner:

$$M_2 + 2P = M_2P_2$$

where M stands for an ACD monomer, M2 for an ACD dimer, and P for a peptide. The ACD is dimeric under these conditions due to an interdimer disulfide bond involving C137 from both subunits. We note, however, that we cannot rule out a sequential binding model, as the observed NMR signals in fast exchange could also contain contributions from singly bound peptide forms of the ACD (Harkness et al., 2020). For resonances in fast exchange, the chemical shifts would reflect an ensemble-averaged position of the free dimer, the dimer with one peptide bound, and the dimer with two peptides bound (Harkness et al., 2020):

$$M_2 + 2P = M_2P + P = M_2P_2$$

Our CSP data cannot differentiate between concurrent and sequential binding models; however, we note that previous native mass spectrometry experiments, which can resolve individual components in a heterogenous mixture, detected singly bound forms of the ADC from ABC (Hilton et al., 2013a). For fitting CSPs from resonances that were in fast exchange to equation 2, the following...
residues were included: T91, D93, W95, W95 side chain, S98, L99, D100, A105, I120, K123, R140, Y142, L144, G147, V148, D149, T151, V153, S154, S155, S156, L157, T162, L163, T164, A167. For resonances that did not have final, peptide-bound chemical modification, even when resonances are not in fast exchange (equation 2). Residues included in the global fit were as follows: T91, D93, W95, W95 side chain, S98, L99, D100, A105, D107, L109, T110, K112, G116, E119, I120, K123, G132, R140, Y142, L144, G147, V148, D149, T151, V153, S154, S155, S156, L157, T162, L163, T164, and A167. For resonances that did not have final, peptide-bound chemical shifts available (K112, T151, S155, S156, L157), the peak positions were estimated based on the temperature titration (Appendix Fig S6) and the CPMG $\Delta \omega_{\text{iso}}$ values (Appendix Table S1).

$^{15}$N CPMG RD data were recorded on $^2$H,$^1$N-chSP27 at both 11.7 and 14.1 T (500 and 600 MHz $^1$H Larmor frequency) at 25°C. This enables the extraction of accurate parameters from analysis of the CPMG RD data by globally fitting data from different static magnetic field strengths. Datasets were collected with 70° × 512° complex points in $t_1 \times t_2$ with maximum acquisition times of 39 and 64 ms, respectively. A pseudo-third dimension was encoded by a variable delay between 180° refocusing pulses in a CPMG pulse train ($\tau_{\text{CPMG}} = 4\nu_{\text{CPMG}}^{-1}$), which were applied during a fixed relaxation delay, $T_{\text{CPMG}}$, of 39 ms. Datasets included 19 values of $\nu_{\text{CPMG}}$ with one duplicated value included for error analysis. Eight scans were collected per FID with an interscan relaxation delay of 3 s, leading to a duration of 18.3 h per spectrum. The effective transverse relaxation rates ($R_{\text{2,eff}}$) were calculated with the following equation:

$$R_{\text{2,eff}}(\nu_{\text{CPMG}}) = \frac{-1}{T_{\text{CPMG}}} \ln \left( \frac{I_{\text{CPMG}}}{I_0} \right)$$

In equation 5, $I_0$ stands for the intensity of a peak in a reference spectrum recorded without the $T_{\text{CPMG}}$ delay and $I_{\text{CPMG}}$ is the intensity obtained with the $T_{\text{CPMG}}$ delay and the corresponding value of $\nu_{\text{CPMG}}$.

In the CPMG RD experiments, the WT peptide was added to a final concentration of 80 µM, whereas P182L peptide was added at 200 µM. The protein concentration was 1.5 mM for both samples. To assess if the measured dispersions arose from inter- or intramolecular events, we recorded a second experiment at 600 MHz only with a different amount of peptide (23 µM for WT and 300 µM for P182L). The observed change in dispersions (Appendix Fig S4) indicated that the exchange was intermolecular in nature and thus reports on peptide binding. Moreover, residues with dispersions were within 4 Å of the peptide binding site. Two exceptions are T151 and S158, which are greater than 4 Å from the peptide but likely sense the N- and C-terminal residues of the peptide, E178 and E186, which were either absent (E178) or did not yield electron density (E186) in the X-ray structure (PDB: 4mjh). Two residues that are close to the peptide are V111 and S155, and these residues yield small dispersions ($R_{\text{ex}} < 2$ s$^{-1}$) that indicate a small $^{15}$N $\Delta \omega_{\text{iso}}$, even though the V111 backbone carbonyl is hydrogen-bonded to T184 in the peptide (Fig 1 E; V111-O-T184(HN) and S155 is ca. 3 Å from V183 in the $^{181}$PV183 motif. Despite the small $^{15}$N dispersions, the V111 and S155 resonances both become broadened during the peptide titration (Fig 3A, Appendix Figs S5 and S8A), indicative of slow-to-intermediate exchange. In a 2D $^1$H,$^15$N HSQC spectrum, chemical exchange-induced broadening can arise from chemical shift changes to either the $^{15}$N or $^1$H nucleus or both (Waudby et al, 2020). Therefore, the broadening of V111 and S155 presumably arises from large $^1$H chemical shift changes upon peptide binding, with $\Delta \omega_{\text{ini}}$ = 0.3 ppm and $\Delta \omega_{\text{fin}}^{V111} = 0.5$ ppm, respectively, corresponding to 1,131 rad/s and 1,885 rad/s at 14.1 T. By contrast, peptide binding does not significantly affect the $^{15}$N chemical shifts of V111 and S155 ($\Delta \omega_{\text{ini}}^{V111} = 0.2$ ppm, $\Delta \omega_{\text{fin}}^{S155} = 0.1$ ppm; 90 rad/s and 45 rad/s at 14.1 T). Thus, the $^{15}$N dispersions arise from residues that are in the immediate vicinity of the bound peptide and experience significant $^{15}$N chemical shift changes upon binding.

Residues were fit to a model of two-state chemical exchange using the CATIA software (Vallurupalli et al, 2008) in which all residues shared the same $p_B$ and $k_{\text{ex}}$ value, with locally fit values of $\Delta \omega_{\text{iso}}$ and the intrinsic transverse relaxation rate $R_{\text{2,eff}}$. A total of 10 residues each from the WT and P182L peptide datasets were included in the global fit: T110, K112, T113, K114, T151, V153, S154, S156, L157, and S158 (Appendix Table S1, Appendix Fig S8). These residues were selected based on a large increase in $R_{\text{2,eff}}$ in the presence of peptide as compared to in the absence of peptide (Appendix Fig S9), where $R_{\text{2,eff}}$ is defined as the difference between $R_{\text{2,eff}}$ values at the lowest and highest $\nu_{\text{CPMG}}$ fields. In oxidized cHSP27, residues D129, E130, R136, C137, and F138 also show dispersions, but these residues were not included in the fit, as they arise from processes that are not related to peptide binding (Alderson et al, 2019). Between the two CPMG RD datasets derived from WT and P182L peptides, there is a large degree of similarity in the fitted $^{15}$N $\Delta \omega_{\text{iso}}$ values (Appendix Fig S10), with an RMSD of 0.27 ppm. Because the $\Delta \omega_{\text{iso}}$ values reflect the chemical shift changes upon binding to peptide, this agreement between the two independently fit datasets signifies the similarity of the conformations of the peptide-bound forms of cHSP27.

To convert the fitted $p_B$ and $k_{\text{ex}}$ values into $k_{\text{on}}$ and $k_{\text{off}}$, and calculate the $K_d$, the following equations were used:

$$k_{\text{ex}} = k_{\text{on}}[L]_{\text{free}} + k_{\text{off}}$$

$$k_{\text{off}} = (1 - p_B)k_{\text{ex}}$$

$$k_{\text{on}} = \frac{p_B k_{\text{ex}}}{[L]_{\text{free}} - p_B[L]}$$

$$k_{\text{d}} = \frac{k_{\text{off}}}{k_{\text{on}}}$$

where $[L]_{\text{free}}$ is the concentration of free ligand (peptide), $[L]_t$ is the total concentration of ligand (peptide), and $[P]$ is the concentration of protein. A table of $K_{\text{d}}, k_{\text{on}},$ and $k_{\text{off}}$ values derived from CPMG RD is included (Appendix Table S2) with the associated energetics (Appendix Table S3).

Two- or three-state binding model

With knowledge of the $K_d$, protein concentration, and ligand concentration, the expected percentage of bound ligand given a two-state interaction can be calculated as follows:
\[ p_{\text{calc}} = \frac{K_d + [L]_t + [P]_t}{2|P|_t} - \frac{(K_d + [L]_t + [P]_t)^2 - 4[L]_t[P]_t}{2|P|_t} \]  

where \([L]_t\) and \([P]_t\) refer to the total concentration of ligand (peptide) and protein (cHSP27), respectively. Thus, at 80 \(\mu\)M of added WT peptide in the presence of 1.5 mM protein for a \(K_d\) of 125 \(\mu\)M, approximately 4.9% of cHSP27 should be bound. For the P182L peptide at a concentration of 200 \(\mu\)M in the presence of 1.5 mM protein for a \(K_d\) of 1,200 \(\mu\)M, approximately 7.2% of cHSP27 should be bound. These calculations yield significantly larger values of \(p_{\text{th}}\) than what was experimentally measured by CPMG RD: 2.4 and 2.0% for WT and P182L, respectively.

While the CSP (Fig 3), lineshape (Appendix Fig S5), and CPMG RD (Fig 4, Appendix Figs S8 and S9) data all fit well to a model of two-state binding, with values of reduced \(\chi^2\) near 1.5 for the CPMG RD fitting, the potential presence of a third state is evident from the discrepancy between the \(K_d\) from CSP data (equation 11) and the \(K_d\) measured by CPMG RD. Moreover, the kinetic parameters extracted from the lineshape analysis with the software TITAN (Appendix Fig S5) and the large fitted values of \(\Delta R_2 (R_{2,\text{bound}} - R_{2,\text{free}})\) (Appendix Fig S7B and C) also point to the presence of a third state.

Thus, the discrepancy in binding affinity as measured by CSPs, lineshape fitting, and CPMG RD could arise from a third state. This is exemplified by the disappearance of NMR signal intensity from residues in the \(\beta4/\beta8\) groove (slow exchange) early in the titration at 25°C (Fig 3A and B), which then do not recover their intensity at the end of the titration with \(ca.\) 95% of the peptide-bound form (Appendix Fig S6A). The intensity is only recovered at higher temperatures (Appendix Figs S6B and S7A), which suggests that the conformational exchange event responsible for the broadening at 25°C has become sufficiently rapid so as to shift the exchange regime from intermediate to fast on the chemical shift timescale. The source of the missing intensity in the titrations, and lower than expected \(p_{\text{th}}\) values in the CPMG RD analysis, could be caused by significant heterogeneity of the peptide when bound to chSP27, leading to multiple interconverting states on the micro-to-millisecond timescale. Multiple conformations of peptide-bound ABC were previously identified from NMR (Delbecq \textit{et al}, 2012), with such heterogeneity perhaps arising from the palindromic nature of the ABC peptide (Ac-PERTIPITREK-NH\(_2\); palindrome italicized). However, while HSP27 does not have a palindromic sequence, it does have multiple IxI/V motifs: the canonical \(^{181}\text{IPV}^{183}\) motif as well as the \(^{171}\text{ITI}^{181}\) motif. The fact that both CSP and CPMG RD data are well-fit to a model of two-state chemical exchange thus implies that the third state rapidly interconverts with one of the two states probed here. Therefore, a plausible binding model may look like one the scheme below:

\[ M_2 + 2P = \{M_2P_2\}_A = \{M_2P_2\}_B \]  

where the two different bound forms interconvert, which is similar to a previous NMR report (Korzhnev \textit{et al}, 2009). As mentioned, the region near the IxI/V motif in HSP27 contains a second possible binding site, \(^{179}\text{ITI}^{181}\). There may be conversion between IxI/V-bound states on the micro-to-millisecond timescale. Alternative explanations may be segmental motions within the bound peptide or a lock-and-dock type of binding mechanism in which the peptide is initially flexibly tethered before stably binding. While comparing the two different bound states identified in cHSP27 remains beyond the scope of this paper, the \(^{15}\text{N} \Delta\omega_1\) values (i) are highly similar for the WT and P182L peptides (Appendix Fig S9), (ii) seem to agree with the chemical shift changes directly observed in the 2D \(^{1}H,^{15}\text{N}\) HSQC spectrum of the peptide-bound state (Appendix Fig S6), and (iii) show excellent correspondence when fit with a naive two-state model or the global three-state model (vide infra) (Appendix Figs S8 and S11). Collectively, these results suggest that the conformations of the peptide-bound forms are highly similar between the WT and P182L forms and that the CPMG RD and titration datasets are probing the same end-state conformation. The two-state fits, while sufficient to obtain qualitative insight, do not agree quantitatively. Therefore, we sought to fit the CPMG RD and titration datasets globally.

The specific numerical challenges when comparing two- and three-state analyses have been addressed (Neudecker \textit{et al}, 2006). A robust three-state analysis of CPMG RD data requires a large amount of data in order to accurately traverse the rugged parameter space such that the true minimum is reached (Neudecker \textit{et al}, 2006). In lieu of such data, we performed a global analysis of the data by imposing the \(K_d\) measured by CSPs and lineshape analysis on the CPMG RD data. Thus, we fixed the value of \(p_{\text{th}}\) to that expected based on the \(K_d\) and known concentrations of protein and ligand. In addition, to account for the multiple exchanging conformations in the bound state, we allowed the parameter \(\Delta R_2 = R_{2,B} - R_{2,A}\) to adopt non-zero values. In this notation, \(R_{2,A}\) is the intrinsic transverse relaxation rate of the ground state (i.e., \(R_{2,0}\) and \(R_{2,B}\) is the transverse relaxation rate of the excited state. Large, non-zero values of \(R_{2,B}\) would be expected to arise from exchange within the bound state on the micro-to-millisecond timescale. Thus, we fit the CPMG RD data at 500 and 600 MHz using a global value of \(k_{\text{ex}}\), local values of \(\Delta\omega_1, R_{2,A}, R_{2,B}\), and a fixed global value of \(p_{\text{th}}\). By fitting the data as such, we obtain highly similar values of \(^{15}\text{N} \Delta\omega_1\) that agree with the standard two-state fitting procedure in which the fitting is performed with \(k_{\text{ex}}\) and \(p_{\text{th}}\) globally floated alongside locally fit values of \(\Delta\omega_1\) with \(\Delta R_2 = 0\) (Appendix Fig S11). The reduced \(\chi^2\) values are essentially identical between the two fitting methods: 1.55 and 1.39 for the naive two-state and the global method, respectively. In addition, the fitted \(^{15}\text{N} \Delta\omega_1\) values agree very well between the two fitting methods (RMSD = 0.37 ppm).

**Molecular dynamics simulations**

All-atom MD simulations of peptides containing the IxI/V motif and the P182L variant were performed using the Gromacs version 4.5.3 simulation package (Berendsen \textit{et al}, 1995) with the AMBER99SB-ILDN force field and the TIP3P water model. To obtain a starting conformation of the IxI/V-containing peptide, chain B comprising residues \(^{179}\text{ITIPVTTE}^{186}\) of HSP27 was extracted from the crystal structure of the ACD bound to its IxI/V motif (PDB: 4mjh). The missing atoms were added with the Modeller web server (Fiser \textit{et al}, 2000). The P182L variant of the peptide was obtained by \textit{in silico} mutagenesis of the P182 residue using PyMOL. After adding the missing atoms, including hydrogens, the WT and P182L peptides, respectively, contained 134 and 139 atoms.

Each MD simulation was performed in a rhombic dodecahedron of size 5.30 by 5.30 by 3.75 nm, which contained 3403 (WT) or 3401 (P182L) water molecules and one sodium ion to maintain
Bioinformatic analyses

[V/I][V/I] motifs were quantified in the reference human proteome that contained only the longest transcript of each gene, with the UniProt Proteome ID UP000005640 (accessed May 2019). We predicted regions of intrinsic disorder comprising 20 residues or longer by running the DISOPRED3 software (Jones & Cozzetto, 2015) with default settings and the UniRe90 database. An in-house Python script making use of the Biopython package (Cock et al., 2009) was written to search for and count specific peptide motifs within the proteome ($M_{\text{proteome}}$) and the database of disordered regions ($M_{\text{disordered}}\subseteq M_{\text{proteome}}$). To count specifically within structured regions of the proteome ($M_{\text{structured}}$), we subtracted $M_{\text{disordered}}$ from $M_{\text{proteome}}$ for each queried tripeptide $j$ (1, ..., $N$) in which the central position was iterated over each amino acid $i$ (1, ..., 20), as such:

$$M_{\text{structured}} = \sum_{j=1}^{N} \sum_{i=1}^{20} \left[ M_{\text{proteome},i} - M_{\text{disordered},i} \right]_j$$  \hspace{1cm} (13)

Removing the summation over $i$ in equation 13 yields the count of specific tripeptides that include a fixed amino acid at the central position, e.g., [V/I][V/I]. To calculate the expected number of peptide motifs found in each database based on amino acid frequencies, we used the following equation:

$$N_{r,n} = M_{r,n} \prod_{q=1}^{n} p_{r,AA_q}$$  \hspace{1cm} (14)

where $p_{r,AA}$ is the frequency of amino acid $AA$ in the database $r$ ($r = \{\text{proteome, structured, disordered}\}$) and $M_{r,n}$ is the total number of peptides of length $n$ in the database $r$. The product sum is calculated by computing $p_{r,AA}$ iteratively for each position $q$ in the queried motif ($q = 1, 2, \ldots, n$). This yields $N_{r,n}$, the expected number of peptides of length $n$ in the database $r$. This assumes that each amino acid in the queried peptide motif has an independent probability of appearing next to any other amino acid, and therefore, we do not account for selective pressures imparted by, e.g., co-evolution of specific motifs. As an illustrative example, the queried tripeptide VSI within the database of disordered regions ($M_{\text{disordered},3} = 2,945,909$) with frequencies of Val, Ser, and Ile corresponding to $p_{\text{disordered, val}} = 0.04440$, $p_{\text{disordered, ser}} = 0.1195$, and $p_{\text{disordered, ile}} = 0.0251$ yields an expected total of 392 VSI motifs. This value agrees closely with the observed number of VSI motifs (376).

To assess statistical significance of the observed numbers of motifs, i.e., to test if the $[V/I][V/I]$ motifs can be accurately described by the underlying amino acid frequencies, we calculated $\chi^2$ values:

$$\chi^2 = \sum_{i,j} \frac{\text{observed}_i - \text{expected}_i}{\text{expected}_i}$$  \hspace{1cm} (15)

For the four motifs (IxI, IxV, VxI, VxV), the total $\chi^2$ values $(\chi^2_{\text{tot}})$ were computed for each amino acid $x = \{A, C, D, \ldots, V, W, Y\}$, with expected values determined by equation 14 based on amino acid frequencies from the databases of structured or disordered regions:

$$\chi^2_{\text{tot}} = \sum_{j=1}^{4} \sum_{i=1}^{20} \frac{\left( M_{\text{observed},j,i} - M_{\text{expected},j,i} \right)^2}{M_{\text{expected},j,i}}$$  \hspace{1cm} (16)

where the indices $i$ and $j$, respectively, refer to the amino acid at position $x = \{A, C, D, \ldots, V, W, Y\}$ and the queried motif (IxI, IxV, VxI, VxV); the symbol $(M_{\text{observed}})$ refers to the observed number of $j$ motifs with residue type $x = i$ in the queried database; and $(M_{\text{expected},j,i})$ refers to the calculated number of $j$ motifs with residue type $x = i$ in the queried database (obtained with equation 14). When collectively analyzing the four motifs for either the disordered or structured region database, there is a total of $\nu = 76$ degrees of freedom. The $\chi^2_{\text{tot}}$ values are 2,849.9 and 1,081.2 for the structured and disordered regions, respectively. The null hypothesis is rejected, as the obtained $P$-values are highly significant, i.e., $P(\chi^2(\nu > 119.85) = 0.001$ for $\nu = 76$. Therefore, the frequency of $[V/I][V/I]$ motifs cannot be described by amino acid frequencies alone.

The Python code that was used for these analyses and the list of disordered regions longer than 20 residues are available from GitHub (https://github.com/reidalderson/bioinformatics).

Data availability

This study includes no data deposited in external repositories.

Acknowledgements

We are grateful to Heath Ecroyd (University of Wollongong) and Josee N. Lavioie (University of Laval) for, respectively, providing the HSP27 and BAG3-GFP expression plasmids, Erik Marklund (Uppsala University) and Matteo T. Degiacomi (Durham University) for insightful discussions, Georg K. A. Hochberg (Max Planck Institute for Terrestrial Microbiology) for analysis of HSP27 orthologues, and Katrien Spaus of the VIB CMN Neuroics Support Facility and Vicky De Winter for assistance in expansion microscopy sample preparation and cloning, respectively. We thank Michaela Auer-Grumbach (Medical University of Vienna, Austria) for providing the fibroblasts of the P182L patient, which were used to generate iPSCs. We thank former laboratory members Mansour Haidar and Thomas Geuens for help with the interactomics experiment, which
was reanalyzed in this study. We also thank Ite Verstraeten and Nik Brusse-
fers for assistance with experiments. This research was supported in part by the University of Antwerp (TOP-BOF to V. T. and DOC-PRO4 PhD project to J. V. L. and V. T.); the Research Foundation-Flanders (FWO-Vlaanderen; to V. T.); the Medical Foundation Queen Elisabeth (GSKE; to V. T.); the American Muscle Dysrophy Association (MDA; to V. T.); the Association Belge contre les Maladies Neuromusculaires (ABMM; to E. A. and V. T.); the Rotary “Hope in Head” program (to E. A. and V. T.); and the H2020 Solve-RD program “Solving the unsolved rare diseases” under grant agreement 2017-779 257 (to V. T.). E. A. is supported by a FWO Postdoctoral grant (Project number 76110). V. T. is a member of the μNEURO Center of Excellence of the University of Antwerp. T. R. A. acknowledges funding from the NIDDK and the NIH Oxford-
Cambridge Scholars Program. A. J. B. holds a David Phillips Fellowship from the Biotechnology and Biosciences Research Council (BB/I014346/1). J. L. P. B. thanks the Engineering and Physical Sciences Research Council (EP/I01835X/1) and Biotechnology and Biosciences Research Council (BB/I018082/1).

Author contributions
TRA, EA, BA, VT, AJB, and JLPB conceptualized the study. TRA, EA, BA, IP, JVL, HYG, MAW, JML, VT, AJB, and JLPB involved in investigation. TRA, EA, BA, VT, and JLPB wrote original draft. TRA, EA, BA, IP, JVL, HYG, MAW, JML, VT, AJB, and JLPB involved in writing—reviewing and editing.

Conflict of interest
The authors declare that they have no conflict of interest.

References

Ackerley S, James PA, Kalli A, French S, Davies KE, Talbot K (2006) A mutation in the small heat-shock protein HSPB1 leading to distal hereditary motor neuronopathy disrupts neurofilament assembly and the axonal transport of specific cellular cargoes. Hum Mol Genet 15: 347–354

Adriaenssens E, Geuens T, Baets J, Echaniz-Laguna A, Timmerman V (2017) Novel insights in the disease biology of mutant small heat shock proteins in neuromuscular diseases. Brain 140: 2541–2549

Adriaenssens E, Tesiasco B, Mediani L, Asselbergh B, Crippa V, Antonini F, Carra S, Poletti A, Timmerman V (2020) BAG3 Pro209 mutants associated with myopathy and neuromuscular sequester chaperones of the CASA-complex in aggresomes. Sci Rep 10: 8755

Alderson TR, Benesch JLP, Baldwin AJ (2017) Proline isomerization in the C-terminal region of HSP27. Cell Stress Chaperones 22: 639–651

Alderson TR, Roche J, Gastall HY, Dias DM, Pritiñac I, Ying J, Bax A, Benesch JLP, Baldwin AJ (2019) Local unfolding of the HSP27 monomer regulates chaperone activity. Nat Commun 10: 1068

Alderson TR, Ying J, Bax A, Benesch JLP, Baldwin AJ (2020) Conditional disorder in small heat-shock proteins. J Mol Biol 432: 3033–3049

Almeida-Souza L, Goethals S, de Winter V, Dierick I, Gallardo R, Van Durme J, Irboi J, Gettemans J, Rousseau F, Schymkowitz J et al (2010) Increased monomerization of mutant HSPB1 leads to protein hyperactivity in charcot-marie-tooth neuropathy. J Biol Chem 285: 12778–12786

Arrigo AP (2001) HSP27: novel regulator of intracellular redox state. IUBMB Life 52: 303–307

Balana AT, Levine PM, Mukherjee S, Pedowitz NJ, Moon SP, Takahashi TT, Becker CFW, Pratt MR (2019) O-GlcNAcylation of small heat shock proteins enhances their anti-amyloid chaperone activity. bioRxiv https://doi.org/10.1101/869909 [PREPRINT]

Baldwin AJ, Hilton GR, Lioe H, Bagnéris C, Benesch JLP, Kay LE (2011) Quaternary dynamics of αβ-crystallin as a direct consequence of localised tertiary fluctuations in the C-terminus. J Mol Biol 413: 310–320

Baldwin AJ, Kay LE (2009) NMR spectroscopy brings invisible protein states into focus. Nat Chem Biol 5: 808–814

Baldwin AJ, Walsh P, Hansen DF, Hilton GR, Benesch JLP, Sharpe S, Kay LE (2012) Probing dynamic conformations of the high-molecular-weight αβ- crystallin heat shock protein ensemble by NMR spectroscopy. J Am Chem Soc 134: 15343–15350

Barisic N, Claesens KY, Sirotkovic-Skerlev M, Lofgren A, Nelis E, De Jonghe P, Timmerman V (2008) Charcot-marie-tooth disease: a clinico-genetic confrontation. Ann Hum Genet 72: 416–441

Basha E, O’Neill H, Vierling E (2012) Small heat shock proteins and α-crystallins: dynamic proteins with flexible functions. Trends Biochem Sci 37: 106–117

Baughman HER, Clouser AF, Klevit RE, Nath A (1980) HspB1 and Hsc70 chaperones engage distinct tau species and have different inhibitory effects on amyloid formation. J Biol Chem 293: 2687–2700

Baughman HER, Pham TT, Adams CS, Nath A, Klevit RE (2020) Release of a disordered domain enhances HspB1 chaperone activity toward tau. Proc Natl Acad Sci USA 117: 2923–2929

Beijer D, Baets J (2020) The expanding genetic landscape of hereditary motor neuropathies. Brain 143: 3540–3563

Berendsen HJC, van der Spoel D, van Drunen R (1995) GROMACS: a message-passing parallel molecular dynamics implementation. Comput Phys Commun 91: 43–56

Bova MP, Yaron O, Huang Q, Ding L, Haley DA, Stewart PL, Horwitz J (1999) Mutation R120G in B-crystallin, which is linked to a desmin-related myopathy, results in an irregular structure and defective chaperone-like function. Proc Natl Acad Sci USA 96: 6137–6142

Breuy JM, Duscescu C, Bonnlaud P, Ravagnan L, Susin SA, Diaz-Latoud C, Gurbuxani S, Arrigo AP, Kroemer G, Solary E et al (2000) Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2: 645–652

Bussi G, Donadio D, Parrinello M (2007) Canonical sampling through velocity rescaling. J Chem Phys 126: 14101

Carra S, Seguin SJ, Lambert H, Landry J (2008) HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. J Biol Chem 283: 1437–1444

Carver JA, Esposito G, Schwedersky GA, Gaestel M (1995) 1H NMR spectroscopy reveals that mouse Hsp25 has a flexible C-terminal extension of 18 amino acids. FEBS Lett 396: 305–310

Carver JA, Grossas AB, Ercoid H, Quinlan RA (2017) The functional roles of the unstructured N- and C-terminal regions in αβ-crystallin and other mammalian small heat-shock proteins. Cell Stress Chaperones 22: 627–638

Chalova AS, Sudnitsyna MV, Strelkov SV, Gusev NB (2014) Characterization of human small heat shock protein HspB1 that carries C-terminal domain mutations associated with hereditary motor neuron diseases. Biochim Biophys Acta 1844: 2116–2126

Chen F, Tillberg PW, Boyden ES (2015) Optical imaging. Expansion microscopy. Science 347: 543–548

Chozinski TJ, Halpern AR, Okawa H, Kim H-J, Tremel GJ, Wong ROL, Vaughan JC (2016) Expansion microscopy with conventional antibodies and fluorescent proteins. Nat Methods 13: 485–488

Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10: 86–103
Clouser AF, Baughman HE, Basanta B, Guttmann M, Nath A, Klevit RE (2019) Interplay of disordered and ordered regions of a human small heat shock protein yields an ensemble of ‘quasi-ordered’ states. Elife 8: e50259
Clouser AF, Klevit RE (2017) pH-dependent structural modulation is conserved in the human small heat shock protein HSPB1. Cell Stress Chromosom 22: 569–575
Cock PJ, Antao T, Chang JT, Chapman BA, Cox CJ, Dalke A, Friedberg I, Hamelryck T, Kauff F, Wilczynski B et al (2009) Biopython: freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics 25: 1422–1423
Collier MP, Alderson TR, de Villiers CP, Nicholls D, Castiglione H, Allison TM, Degiacomi MT, Jiang H, Mlynek G, Fürst DO et al (2019) HspB1 phosphorylation regulates its intramolecular dynamics and mechanosensitive molecular chaperone interaction with filamin C. Sci Adv 5: eaav4821
D’Yedwalle C, Krishnan J, Chiheb DM, Van Damme P, Irobi J, Kozikowski AP, Bergh PE, Timmerman V, Robberecht W, Van Den Bosch L (2008) HDAC6 inhibitors reverse axonal reorganization in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 17: 968–974
Davey NE, Van Roey K, Weerethirij R, Toedt G, Uyar B, Altenberg B, Budd A, Diella F, Dinkel H, Gibson TJ (2012) Attributes of short linear motifs. Mol Biosyst 8: 268–281
Delafore E, Kragelj J, Tengo L, Palencia A, Millés S, Bouguignies G, Salvi N, Blackledge M, Jensen MR (2018) Deciphering the dynamic interaction profile of an intrinsically disordered protein by NMR exchange spectroscopy. J Am Chem Soc 140: 1148–1158
Delagio F, Grzesiek S, Vuister GW, Zhu G, Pfeiffer J, Bax A (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6: 277–293
Delbecq SP, Jehle S, Klevit R (2012) Binding determinants of the small heat shock protein αB-crystallin: recognition of the ‘xIβ’ motif. EMBO J 31: 4587–4594
Demers J-P, Mittermaier A (2009) Binding mechanism of an SH3 domain studied by NMR and ITC. J Am Chem Soc 131: 4355–4367
Dierick I, Baets J, Irobi J, Jacobs A, De Vriendt E, Deconinck T, Merlini L, Van den Bergh P, Rasic VM, Robberecht W et al (2008) Relative contribution of mutations in genes for autosomal dominant distal hereditary motor neuropathies: a genotype-phenotype correlation study. Brain 131: 1217–1227
Echaniz-Laguna A, Geuens T, Petiot P, Péron Y, Adriaenssens E, Haidar M, Capponi S, Maisonobe T, Fourrier E, Dubourg O et al (2017) Axonal neuropathies due to mutations in small heat shock proteins: clinical, genetic, and functional insights into novel mutations. Hum Mutat 38: 556–568
Evgrafov OV, Mersiyanova I, Irobi J, Van Den Bosch L, Dierick I, Leung CL, Schagina O, Verpoorten N, Van Impe K, Fedotov V et al (2004) Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 36: 602–606
Fiser A, Do RK, Šali A (2000) Modeling of loops in protein structures. Protein Sci 9: 1753–1773
Freilich R, Betegon M, Tse E, Mok S-A, Julien O, Agard DA, Southworth DR, Takeuchi K, Gestwicki JE (2018) Competing protein-protein interactions regulate binding of Hsp27 to its client protein tau. Nat Commun 9: 4563
Fuchs M, Poirier DJ, Seguin SJ, Lambert H, Carra S, Charette SJ, Landry J (2010) Identification of the key structural motifs involved in HspB8/HspB6-Bag3 interaction. Biochem J 425: 245–257
Ganassi M, Mateju D, Bigi I, Mediani L, Poser I, Lee HO, Seguin SJ, Morelli FF, Vinet J, Leo G et al (2016) A surveillance function of the HSPB8-BAG3-HSP70 chaperone complex ensures stress granule integrity and dynamism. Mol Cell 63: 796–810
Geuens T, De Winter V, Rajan N, Achsel T, Mateju L, Almeida-Souza L, Asselbergh B, Bouhy D, Auer-Grumbach M, Bagni C et al (2017) Mutant HSPB1 causes loss of translational repression by binding to PCBP1, an RNA binding protein with a possible role in neurodegenerative disease. Acta Neuropathol Commun 5: 5
Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatens P, Boon R, Or dová L, Patel A, Welters M, Vanwelden T et al (2017) HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat Commun 8: 861
Gusev NB, Bogatcheva NV, Marston SB (2002) Structure and properties of small heat shock proteins (sHsps) and their interaction with cytoskeleton proteins. Biochemistry 67: 511–519
Haidar M, Asselbergh B, Adriaenssens E, De Winter V, Timmermans J-P, Auer-Grumbach M, Juneja M, Timmerman V (2019) Neuropathy-causing mutations in HSPB1 impair autophagy by disturbing the formation of SQSTM1/p62 bodies. Autophagy 15: 1051–1068
Hansen DF, Vullurupalli P, Kay LE (2008a) An improved 15N relaxation dispersion experiment for the measurement of millisecond time-scale dynamics in proteins. J Phys Chem B 112: 5898–5904
Hansen DF, Vullurupalli P, Lundström P, Neudecker P, Kay LE (2008b) Probing chemical shifts of invisible states of proteins with relaxation dispersion NMR spectroscopy: how well can we do? J Am Chem Soc 130: 2667–2675
Hansen DF, Vullurupalli P, Kay LE (2009) Measurement of methyl group motional parameters of invisible, excited protein states by NMR spectroscopy. J Am Chem Soc 131: 12745–12754
Harkness RW, Toyama Y, Kay LE (2020) Analyzing multi-step ligand binding reactions for oligomeric proteins by NMR: theoretical and computational considerations. J Magn Reson 318: 106802
Haslebeck B, Vierling E (2015) A first line of stress defense: small heat shock proteins and their function in protein homeostasis. J Mol Biol 427: 1537–1548
Hilton GR, Hochberg GKA, Laganowsky A, McGinnigle SI, Baldwin AJ, Benesch JLP (2013a) Motor neuronal axonal transport defects in motor neurons derived from FUS-ALS patients. Philos Trans R Soc Lond B Biol Sci 368: 20110405
Hilton GR, Lioe H, Stengel F, Baldwin AJ, Benesch JLP (2013b) Small heat shock-proteins: paramedics of the cell. Top Curr Chem 328: 69–98
Hochberg GKA, Benesch JLP (2014) Dynamical structure of αB-crystallin. Prog Biophys Mol Biol 115: 11–20
Hochberg GKA, Eccroyd H, Liu C, Cox D, Cascio D, Sawaya MR, Collier MP, Strool J, Carver JA, Baldwin AJ et al (2014) The structured core domain of B-crystallin can prevent amyloid fibrillation and associated toxicity. Proc Natl Acad Sci USA 111: E1562–E1570
Holt C, Raynes JK, Carver JA (2019) Sequence characteristics responsible for protein-protein interactions in the intrinsically disordered regions of caseins, amelogenins, and small heat-shock proteins. Biopolymers 110: e23319
Ishima R, Torchia DA (2006) Accuracy of optimized chemical-exchange parameters derived by fitting CPMG R2 dispersion profiles when R20 ≠ R20b. J Biomol NMR 34: 209–219
Jain S, Wheeler J, Walters R, Agrawal A, Barsic A, Parker R (2016) ATPase-modulated stress granules contain a diverse proteome and substructure. Cell 164: 487–498
Janowska MK, Baughman HER, Woods CN, Klevit RE (2019) Mechanisms of small heat shock proteins. Cold Spring Harb Perspect Biol 11: a034025
heat-shock protein reveals conserved motifs of oligomer plasticity. Structure 26: 1116–1126.e4

Mogk A, Rüger-Herreros C, Bukau B (2019) Cellular functions and mechanisms of action of small heat shock proteins. Annu Rev Microbiol 73: 89–110

Morelli FF, Verbeek DS, Bertacchini J, Vinet J, Mediani L, Marmiroli S, Ceracchi C, Nasi M, De Biasi S, Brunsting JF et al (2017) Aberrant compartment formation by HSPB2 mislocalizes lamin A and compromises nuclear integrity and function. Cell Rep 20: 2100–2115

Muranova LK, Sudnitsyna MV, Strelkov SV, Gusev NB (2020) Mutations in HspB1 and hereditary neuropathies. Cell Stress Chaperones 25: 655–665

Muranova LK, Weeks SD, Strelkov SV, Gusev NB (2015) Characterization of mutants of human small heat shock protein HspB1 carrying replacements in the N-terminal domain and associated with hereditary motor neuron diseases. PloS One 10: e0126248

Nefedova V, Datskevich PN, Sudnitsyna MV, Strelkov SV, Gusev NB (2013) Physico-chemical properties of R140G and K141Q mutants of human small heat shock protein HspB1 associated with hereditary peripheral neuropathies. Biochimie 95: 1582–1592

Nefedova VV, Muranova LK, Sudnitsyna MV, Ryzhavskaya AS, Gusev NB (2015) Small heat shock proteins and distal hereditary neuropathies. Biochem. 80: 1734–1747

Neudecker P, Korzhnev DM, Kay LE (2006) Assessment of the effects of increased relaxation dispersion data on the extraction of 3-site exchange parameters characterizing the unfolding of an SH3 domain. J Biomol NMR 34: 129–135

Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet J-C, Hyman BT, McLean PJ (2006) Small heat shock proteins protect against α-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun 351: 631–638

Palmer AG, Kronke CD, Loria JP (2001) Nuclear magnetic resonance methods for quantifying microsecond-to-millisecond motions in biological macromolecules. Methods Enzymol 339: 204–238

Parrinello M, Rahman A (1981) Polymorphic transitions in single crystals: a new molecular dynamics method. J Appl Phys 52: 7182–7190

Pasta SY, Raman B, Ramakrishna T, Rao CM (2004) The IXI/V motif in the C-terminal extension of alpha-crystallins: alternative interactions and oligomeric assemblies. Mol Vis 10: 655–662

Pipis M, Rossor AM, Laura M, Reilly MM (2019) Next-generation sequencing in Charcot–Marie–Tooth disease: opportunities and challenges. Nat Rev Neurol 15: 644–656

Pritišanac I, Vernon RM, Moses AM, Forman Kay JD (2019) Entropy and information within intrinsically disordered protein regions. Entropy 21: 662

R Foundation for Statistical Computing (2015) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing

Rajagopal P, Liu Y, Shi L, Clooser AF, Klevit RE (2015) Structure of the α-crystallin domain from the redox-sensitive chaperone, HSPB1. J Biomol NMR 63: 223–228

Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8: 2281–2308

Rauch JN, Tse E, Freilich R, Mok S-A, Makley LN, Southworth DR, Gestwicki JE (2017) BAG3 is a modular, scaffolding protein that physically links heat shock protein 70 (Hsp70) to the small heat shock proteins. J Mol Biol 429: 128–141

Rosati A, Graziano V, De Laurenzi V, Pascale M, Turco MC (2011) BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis 2: e141
Rossor AM, Polke JM, Houlden H, Reilly MM (2013) Clinical implications of genetic advances in Charcot–Marie–Tooth disease. *Nat Rev Neurol* 9: 562–571

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B et al (2012) Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9: 676–682

Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 9: 671–675

Schneider R, Maurin D, Communie G, Kragelj J, Hansen MR, Blackledge M (2015) Visualizing the molecular recognition trajectory of an intrinsically disordered protein using multinuclear relaxation dispersion NMR. *J Am Chem Soc* 137: 1220–1229

Schreiber G, Haran G, Zhou HX (2009) Fundamental aspects of protein - Protein association kinetics. *Chem Rev* 109: 839–860

Selcen D, Muntoni F, Burton BK, Pegoraro E, Sewry C, Bite AV, Engel AG (2008) Mutation in BAG3 causes severe dominant childhood muscular dystrophy. *Ann Neurol* 65: 83–89

Shy M, Rebeiro AP, Feely SM, Abreu LA, Tao F, Swenson A, Bacon C, Zuchner S (2018) Mutations in BAG3 cause adult-onset Charcot-Marie-Tooth disease. *J Neurol Neurosurg Psychiatry* 89: 313–315

Stark C, Breitkreutz B-J, Reguly T, Boucher L, Breitkreutz A, Tyers M (2006) BioGRID: a general repository for interaction datasets. *Nucleic Acids Res* 34: D535–D539

Straume O, Shimamura T, Lampa MJG, Carretero J, Øyan AM, Jia D, Borgman CL, Souchay M, Downing SR, Short SM et al (2012) Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. *Proc Natl Acad Sci USA* 109: 8699–8704

Stróżecka J, Chrusciel E, Górnia E, Szymanska A, Ziętkiewicz S, Liberek K (2012) Importance of N- and C-terminal regions of IbpA, *Escherichia coli* small heat shock protein, for chaperone function and oligomerization. *J Biol Chem* 287: 2843–2853

Sugase K, Dyson HJ, Wright PE (2007a) Mechanism of coupled folding and binding of an intrinsically disordered protein. *Nature* 447: 1021–1025

Sugase K, Lansing JC, Dyson HJ, Wright PE (2007b) Tailoring relaxation dispersion experiments for fast-associating protein complexes. *J Am Chem Soc* 129: 13406–13407

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131: 861–872

Theillet F-X, Kalmár L, Tompa P, Han KH, Selenko P, Dunker AK, Daughdrill GW, Uversky VN (2014) The alphabet of intrinsic disorder: I. Act like a Pro: On the abundance and roles of proline residues in intrinsically disordered proteins. *Intrinsically Disord. Proteins* 1: e24360

Timmerman V, Strickland A, Züchner S (2014) Genetics of Charcot-Marie-Tooth (CMT) disease within the frame of the human genome project success. *Genes* 5: 13–32

Ungelegen S, Moayed F, Ho CT, Grosul T, Scharf A, Mashahi G, Tans S, Mayer MP, Mogk A, Bukau B (2016) Small heat shock proteins sequester misfolding proteins in near-native conformation for cellular protection and efficient refolding. *Nat Commun* 7: 13673

Vallurupalli P, Hansen DF, Kay LE (2008) Structures of invisible, excited protein states by relaxation dispersion NMR spectroscopy. *Proc Natl Acad Sci USA* 105: 11766–11771

Vendrely L, Adriaenssens E, Timmerman V (2020) Small heat shock proteins in neurodegenerative diseases. *Cell Stress Chaperones* 25: 679–699

Waudby C, Ovury M, Davis B, Christodoulou J (2020) Two-dimensional NMR lineshape analysis of single, multiple, zero and double quantum correlation experiments. *J Biomol NMR* 74: 95–109

Waudby CA, Ramos A, Cabrita LD, Christodoulou J (2016) Two-dimensional NMR lineshape analysis. *Sci Rep* 6: 24826

Weeks SD, Muranova LK, Heirbaut M, Beelen S, Strelokov SV, Gusev NB (2018) Characterization of human small heat shock protein HSPB1 α-crystallin domain localized mutants associated with hereditary motor neuron diseases. *Sci Rep* 8: 688

Wright PE, Dyson HJ (2014) Intrinsically disordered proteins in cellular signalling and regulation. *Nat Rev Mol Cell Biol* 16: 18–29

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.